WO1998003195A9 - Methods and compositions for modulation of growth response - Google Patents
Methods and compositions for modulation of growth responseInfo
- Publication number
- WO1998003195A9 WO1998003195A9 PCT/US1997/012498 US9712498W WO9803195A9 WO 1998003195 A9 WO1998003195 A9 WO 1998003195A9 US 9712498 W US9712498 W US 9712498W WO 9803195 A9 WO9803195 A9 WO 9803195A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- abl
- cells
- nucleic acid
- tumor
- Prior art date
Links
- 230000004044 response Effects 0.000 title abstract description 22
- 239000000203 mixture Substances 0.000 title description 57
- 230000012010 growth Effects 0.000 title description 37
- 230000000051 modifying Effects 0.000 title description 2
- 201000011510 cancer Diseases 0.000 claims abstract description 31
- 210000004027 cells Anatomy 0.000 claims description 278
- 101710026335 TP53 Proteins 0.000 claims description 207
- 102100019730 TP53 Human genes 0.000 claims description 206
- 230000014509 gene expression Effects 0.000 claims description 112
- 230000000694 effects Effects 0.000 claims description 88
- 150000007523 nucleic acids Chemical class 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 64
- 239000003795 chemical substances by application Substances 0.000 claims description 48
- 210000004881 tumor cells Anatomy 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 230000001404 mediated Effects 0.000 claims description 30
- 241000701161 unidentified adenovirus Species 0.000 claims description 30
- 230000001965 increased Effects 0.000 claims description 29
- 230000003612 virological Effects 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 230000006907 apoptotic process Effects 0.000 claims description 26
- 206010059512 Apoptosis Diseases 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 22
- 210000001519 tissues Anatomy 0.000 claims description 22
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 19
- 239000002502 liposome Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 238000002965 ELISA Methods 0.000 claims description 14
- 238000001890 transfection Methods 0.000 claims description 14
- 241001430294 unidentified retrovirus Species 0.000 claims description 13
- 229960004857 Mitomycin Drugs 0.000 claims description 12
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 12
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 12
- 239000007924 injection Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 10
- 229960004316 cisplatin Drugs 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 9
- 229960004679 Doxorubicin Drugs 0.000 claims description 9
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 9
- 229960005420 Etoposide Drugs 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 210000004072 Lung Anatomy 0.000 claims description 8
- 230000002950 deficient Effects 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 229960002949 Fluorouracil Drugs 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 229940009456 Adriamycin Drugs 0.000 claims description 6
- 210000004185 Liver Anatomy 0.000 claims description 6
- 238000001262 western blot Methods 0.000 claims description 6
- 241000432074 Adeno-associated virus Species 0.000 claims description 4
- 229960000640 Dactinomycin Drugs 0.000 claims description 4
- 108010092160 Dactinomycin Proteins 0.000 claims description 4
- 210000003491 Skin Anatomy 0.000 claims description 4
- 241000700618 Vaccinia virus Species 0.000 claims description 4
- 206010047461 Viral infection Diseases 0.000 claims description 4
- 208000001756 Virus Disease Diseases 0.000 claims description 4
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 230000002601 intratumoral Effects 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 230000017613 viral reproduction Effects 0.000 claims description 4
- 210000001185 Bone Marrow Anatomy 0.000 claims description 3
- 210000002307 Prostate Anatomy 0.000 claims description 3
- 210000000952 Spleen Anatomy 0.000 claims description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 3
- 238000001638 lipofection Methods 0.000 claims description 3
- 210000001938 protoplasts Anatomy 0.000 claims description 3
- 229960001722 verapamil Drugs 0.000 claims description 3
- 210000004369 Blood Anatomy 0.000 claims description 2
- 210000000601 Blood Cells Anatomy 0.000 claims description 2
- 210000004556 Brain Anatomy 0.000 claims description 2
- 210000000481 Breast Anatomy 0.000 claims description 2
- 210000001072 Colon Anatomy 0.000 claims description 2
- 210000004696 Endometrium Anatomy 0.000 claims description 2
- 210000003238 Esophagus Anatomy 0.000 claims description 2
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 claims description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N Genistin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 2
- 210000003128 Head Anatomy 0.000 claims description 2
- 210000003734 Kidney Anatomy 0.000 claims description 2
- 210000001165 Lymph Nodes Anatomy 0.000 claims description 2
- 210000003739 Neck Anatomy 0.000 claims description 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims description 2
- 210000001672 Ovary Anatomy 0.000 claims description 2
- 210000000496 Pancreas Anatomy 0.000 claims description 2
- 210000002784 Stomach Anatomy 0.000 claims description 2
- 210000001550 Testis Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 abstract description 5
- 230000001640 apoptogenic Effects 0.000 abstract description 3
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 102100002185 EP300 Human genes 0.000 description 84
- 101700011490 EP300 Proteins 0.000 description 84
- 101710036042 NOTCH1 Proteins 0.000 description 84
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 70
- 108090001123 antibodies Proteins 0.000 description 43
- 102000004965 antibodies Human genes 0.000 description 43
- 230000027455 binding Effects 0.000 description 43
- 101700048555 CDK2 Proteins 0.000 description 39
- 101710022308 CDKN1A Proteins 0.000 description 39
- 102100002974 CDKN1A Human genes 0.000 description 39
- 101700045377 mvp1 Proteins 0.000 description 39
- 101700033061 GRA5 Proteins 0.000 description 38
- 101700045188 NSG1 Proteins 0.000 description 38
- 101700020165 RHOA Proteins 0.000 description 38
- 101710029715 TCEAL1 Proteins 0.000 description 38
- 101700073473 TPT1 Proteins 0.000 description 38
- 101700009395 orf8 Proteins 0.000 description 38
- 101700012276 wos2 Proteins 0.000 description 38
- 235000018102 proteins Nutrition 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000000523 sample Substances 0.000 description 37
- 230000003321 amplification Effects 0.000 description 35
- 238000003199 nucleic acid amplification method Methods 0.000 description 35
- 108091000081 Phosphotransferases Proteins 0.000 description 31
- 102000001253 Protein Kinases Human genes 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 29
- MBABOKRGFJTBAE-UHFFFAOYSA-N Methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 27
- 239000000047 product Substances 0.000 description 27
- 231100000277 DNA damage Toxicity 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 20
- 230000001939 inductive effect Effects 0.000 description 20
- 230000036191 S Phase Effects 0.000 description 18
- 230000018199 S phase Effects 0.000 description 18
- 239000000427 antigen Substances 0.000 description 18
- 102000038129 antigens Human genes 0.000 description 18
- 108091007172 antigens Proteins 0.000 description 18
- 230000001419 dependent Effects 0.000 description 18
- 238000001514 detection method Methods 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000002708 enhancing Effects 0.000 description 17
- 239000003550 marker Substances 0.000 description 17
- 230000035897 transcription Effects 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 239000003623 enhancer Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 229920000023 polynucleotide Polymers 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000001105 regulatory Effects 0.000 description 13
- 230000035492 administration Effects 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 230000001738 genotoxic Effects 0.000 description 12
- 231100000024 genotoxic Toxicity 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 230000002194 synthesizing Effects 0.000 description 12
- 230000003828 downregulation Effects 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000007792 addition Methods 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 10
- 230000001809 detectable Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002068 genetic Effects 0.000 description 9
- 238000002318 immunoblotting Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- 239000002609 media Substances 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 238000006366 phosphorylation reaction Methods 0.000 description 9
- 230000000865 phosphorylative Effects 0.000 description 9
- 230000001225 therapeutic Effects 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 239000005089 Luciferase Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 230000001413 cellular Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drugs Drugs 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 229920000272 Oligonucleotide Polymers 0.000 description 7
- -1 dipstick Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 210000004962 mammalian cells Anatomy 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 230000001177 retroviral Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000002103 transcriptional Effects 0.000 description 7
- 108010035563 Chloramphenicol O-Acetyltransferase Proteins 0.000 description 6
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 6
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 6
- 102000033147 ERVK-25 Human genes 0.000 description 6
- 108020004999 Messenger RNA Proteins 0.000 description 6
- 229920001850 Nucleic acid sequence Polymers 0.000 description 6
- 238000003782 apoptosis assay Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 230000000295 complement Effects 0.000 description 6
- 201000009910 diseases by infectious agent Diseases 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000003211 malignant Effects 0.000 description 6
- 229920002106 messenger RNA Polymers 0.000 description 6
- 230000005522 programmed cell death Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 230000001131 transforming Effects 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 229920001405 Coding region Polymers 0.000 description 5
- 229920002676 Complementary DNA Polymers 0.000 description 5
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 description 5
- 101710038044 ERVK-6 Proteins 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 108060001084 Luciferase family Proteins 0.000 description 5
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000002168 alkylating agent Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000000977 initiatory Effects 0.000 description 5
- 238000000021 kinase assay Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000035916 transactivation Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 210000000170 Cell Membrane Anatomy 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 241000668709 Dipterocarpus costatus Species 0.000 description 4
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 4
- 101710003775 ERVK-10 Proteins 0.000 description 4
- 101710037030 ERVK-11 Proteins 0.000 description 4
- 101710009283 ERVK-18 Proteins 0.000 description 4
- 101710009286 ERVK-19 Proteins 0.000 description 4
- 101710035700 ERVK-25 Proteins 0.000 description 4
- 101710014468 ERVK-7 Proteins 0.000 description 4
- 101710014482 ERVK-8 Proteins 0.000 description 4
- 101710043924 HERVK_113 Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 101710029649 MDV043 Proteins 0.000 description 4
- 102000007981 Ornithine carbamoyltransferases Human genes 0.000 description 4
- 108091000036 Ornithine carbamoyltransferases Proteins 0.000 description 4
- 102000014961 Protein Precursors Human genes 0.000 description 4
- 108010078762 Protein Precursors Proteins 0.000 description 4
- 101710006375 RNASEH1 Proteins 0.000 description 4
- 101700078434 RT67 Proteins 0.000 description 4
- 102000006601 Thymidine Kinase Human genes 0.000 description 4
- 108020004440 Thymidine Kinase Proteins 0.000 description 4
- 108010067390 Viral Proteins Proteins 0.000 description 4
- 102000016350 Viral Proteins Human genes 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 230000000973 chemotherapeutic Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001613 neoplastic Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000001402 polyadenylating Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 101700086982 rnh Proteins 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 3
- 229950004398 Broxuridine Drugs 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 210000000349 Chromosomes Anatomy 0.000 description 3
- 102000020504 Collagenase family Human genes 0.000 description 3
- 108060005980 Collagenase family Proteins 0.000 description 3
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 description 3
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 description 3
- 101700011961 DPOM Proteins 0.000 description 3
- 102100002070 FOS Human genes 0.000 description 3
- 230000035521 G2 Phase Effects 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 210000003494 Hepatocytes Anatomy 0.000 description 3
- 208000009889 Herpes Simplex Diseases 0.000 description 3
- 206010025650 Malignant melanoma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 101700061424 POLB Proteins 0.000 description 3
- 101700054624 RF1 Proteins 0.000 description 3
- 108050008067 Rad9 Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 3
- 230000036462 Unbound Effects 0.000 description 3
- 210000002845 Virion Anatomy 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 108010084541 asialoorosomucoid Proteins 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 230000025084 cell cycle arrest Effects 0.000 description 3
- 230000023359 cell cycle switching, meiotic to mitotic cell cycle Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 229960002424 collagenase Drugs 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001086 cytosolic Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000002612 dispersion media Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002147 killing Effects 0.000 description 3
- 239000006193 liquid solution Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 3
- 230000003362 replicative Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 108090000464 transcription factors Proteins 0.000 description 3
- 102000003995 transcription factors Human genes 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 238000004450 types of analysis Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 102100008450 AFP Human genes 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 206010001258 Adenoviral infection Diseases 0.000 description 2
- 102100000690 CHL1 Human genes 0.000 description 2
- 101710025159 CMPK1 Proteins 0.000 description 2
- 102000004040 Capsid Proteins Human genes 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108009000097 DNA Replication Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000016615 EC 2.7.7.49 Human genes 0.000 description 2
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 2
- 210000000981 Epithelium Anatomy 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 206010073306 Exposure to radiation Diseases 0.000 description 2
- 108060001038 FOS Proteins 0.000 description 2
- 102000011422 GADD45 protein Human genes 0.000 description 2
- 108091007852 GADD45 protein Proteins 0.000 description 2
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 2
- 108091006078 GTPase-accelerating proteins Proteins 0.000 description 2
- 102000005720 Glutathione Transferase family Human genes 0.000 description 2
- 108010070675 Glutathione Transferase family Proteins 0.000 description 2
- 102100009498 HMGB1 Human genes 0.000 description 2
- 108010014739 HMGB1 Protein Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108090000745 Immune Sera Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 229920002957 Naked DNA Polymers 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 210000004940 Nucleus Anatomy 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102000007584 Prealbumin Human genes 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 2
- 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 2
- 108050002653 Retinoblastoma Protein Proteins 0.000 description 2
- 241000700584 Simplexvirus Species 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 229920002083 cellular DNA Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001351 cycling Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000001963 growth media Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 230000003100 immobilizing Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000001678 irradiating Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000037327 stress response Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000000576 supplementary Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 230000002588 toxic Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 101710025088 66 Proteins 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N ABTS Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 101700033661 ACTB Proteins 0.000 description 1
- 102100011550 ACTB Human genes 0.000 description 1
- 101710032514 ACTI Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 101710027066 ALB Proteins 0.000 description 1
- 101710028063 APCS Proteins 0.000 description 1
- 102100003659 APCS Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- NOFOAYPPHIUXJR-APNQCZIXSA-N Aphidicolin Chemical compound C1[C@@]23[C@@]4(C)CC[C@@H](O)[C@@](C)(CO)[C@@H]4CC[C@H]3C[C@H]1[C@](CO)(O)CC2 NOFOAYPPHIUXJR-APNQCZIXSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- ABIUHPWEYMSGSR-UHFFFAOYSA-N Bromocresol purple Chemical compound BrC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Br)C(O)=C(C)C=2)=C1 ABIUHPWEYMSGSR-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102100000189 CD22 Human genes 0.000 description 1
- 101700020617 CD22 Proteins 0.000 description 1
- 101700024634 CDK16 Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 210000003837 Chick Embryo Anatomy 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 210000003483 Chromatin Anatomy 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 229940109239 Creatinine Drugs 0.000 description 1
- 102000003903 Cyclin-Dependent Kinases Human genes 0.000 description 1
- 108090000266 Cyclin-Dependent Kinases Proteins 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 101710007887 DHFR Proteins 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 230000007118 DNA alkylation Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108091000102 DNA-Binding Proteins Proteins 0.000 description 1
- 102000031025 DNA-Binding Proteins Human genes 0.000 description 1
- 101710028159 DNTT Proteins 0.000 description 1
- 102100002445 DNTT Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013801 Duchenne muscular dystrophy Diseases 0.000 description 1
- 241000725618 Duck hepatitis B virus Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 102000003425 EC 1.14.18.1 Human genes 0.000 description 1
- 108060008724 EC 1.14.18.1 Proteins 0.000 description 1
- 102100010813 EGF Human genes 0.000 description 1
- 101700033006 EGF Proteins 0.000 description 1
- 102000001301 EGF receptors Human genes 0.000 description 1
- 108060006698 EGF receptors Proteins 0.000 description 1
- 101700036757 ERN1 Proteins 0.000 description 1
- 102100016655 ERN1 Human genes 0.000 description 1
- 101700014948 ERN2 Proteins 0.000 description 1
- 102000033180 ERVK-6 Human genes 0.000 description 1
- 101710027967 ERVW-1 Proteins 0.000 description 1
- 229940116977 Epidermal Growth Factor Drugs 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001272 Exogenous DNA Polymers 0.000 description 1
- 102100016764 FYN Human genes 0.000 description 1
- 101700037202 FYN Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 210000003714 Granulocytes Anatomy 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N Guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 102100019126 HBB Human genes 0.000 description 1
- 101710023137 HSP90B1 Proteins 0.000 description 1
- 102100009909 HSP90B1 Human genes 0.000 description 1
- 101710006403 HSPA5 Proteins 0.000 description 1
- 102100015710 HSPA5 Human genes 0.000 description 1
- 230000036499 Half live Effects 0.000 description 1
- 108091005902 Hemoglobin subunit beta Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108090000246 Histone Acetyltransferases Proteins 0.000 description 1
- 102000003893 Histone Acetyltransferases Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 101700082799 IL2RA Proteins 0.000 description 1
- 101700085586 IRE1A Proteins 0.000 description 1
- 101700019719 IRE1B Proteins 0.000 description 1
- 101700015336 ISG20 Proteins 0.000 description 1
- 102100002950 ISG20 Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102000003996 Interferon beta Human genes 0.000 description 1
- 108090000467 Interferon beta Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- QWTDNUCVQCZILF-UHFFFAOYSA-N Isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 108040008094 JUN kinase activity proteins Proteins 0.000 description 1
- 102100002583 KAT2B Human genes 0.000 description 1
- 101700083085 KAT2B Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ZQISRDCJNBUVMM-YFKPBYRVSA-N L-histidinol Chemical compound OC[C@@H](N)CC1=CNC=N1 ZQISRDCJNBUVMM-YFKPBYRVSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710007526 MAP3K14 Proteins 0.000 description 1
- 101710029922 MAPK9 Proteins 0.000 description 1
- 102100005528 MAPK9 Human genes 0.000 description 1
- 102100019155 MDM2 Human genes 0.000 description 1
- 101700032565 MDM2 Proteins 0.000 description 1
- 108010059343 MM Form Creatine Kinase Proteins 0.000 description 1
- 102100015262 MYC Human genes 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241001028048 Nicola Species 0.000 description 1
- 102000006570 Non-Histone Chromosomal Proteins Human genes 0.000 description 1
- 108010008964 Non-Histone Chromosomal Proteins Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 210000001623 Nucleosomes Anatomy 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 101710016786 P/C Proteins 0.000 description 1
- 101700044505 PUB33 Proteins 0.000 description 1
- 101700045570 PUB34 Proteins 0.000 description 1
- 101700046887 PUB35 Proteins 0.000 description 1
- 101700066160 PUB51 Proteins 0.000 description 1
- 101700067511 PUB52 Proteins 0.000 description 1
- 101700068819 PUB53 Proteins 0.000 description 1
- 101700086326 PUB70 Proteins 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 102000016387 Pancreatic Elastase Human genes 0.000 description 1
- 108010067372 Pancreatic Elastase Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- WGVWLKXZBUVUAM-UHFFFAOYSA-N Pentanochlor Chemical compound CCCC(C)C(=O)NC1=CC=C(C)C(Cl)=C1 WGVWLKXZBUVUAM-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 102000012500 Proto-Oncogene Proteins c-crk Human genes 0.000 description 1
- 108010022955 Proto-Oncogene Proteins c-crk Proteins 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 108020004412 RNA 3' Polyadenylation Signals Proteins 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000012121 Retinoblastoma Protein Human genes 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101710017605 Rv2228c Proteins 0.000 description 1
- 102100015622 SCGB1A1 Human genes 0.000 description 1
- 101710010598 SCGB1A1 Proteins 0.000 description 1
- 102100007015 SERPINE1 Human genes 0.000 description 1
- 101710009384 SRC Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710023234 Segment 5 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000011763 Serum Amyloid A Protein Human genes 0.000 description 1
- 108010076895 Serum Amyloid A Protein Proteins 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 241000144282 Sigmodon Species 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000521327 Streptomyces caespitosus Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 108091008153 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 208000000389 T-Cell Leukemia Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 description 1
- 238000003302 UV-light treatment Methods 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 101700021643 VP4A Proteins 0.000 description 1
- 101700028070 VPX Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- VBJHPXDIVMXHJU-UHFFFAOYSA-N Zeocin Chemical compound N=1C(C=2SC=C(N=2)C(=O)NCCCCN=C(N)N)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1[N]C=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C VBJHPXDIVMXHJU-UHFFFAOYSA-N 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 230000000172 allergic Effects 0.000 description 1
- 108010090535 alpha-albumin Proteins 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000000118 anti-eoplastic Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliferant Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 229920002847 antisense RNA Polymers 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 230000001580 bacterial Effects 0.000 description 1
- 108010003152 bacteriophage T7 RNA polymerase Proteins 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000001588 bifunctional Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- BPYKTIZUTYGOLE-IFADSCNNSA-N bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002759 chromosomal Effects 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000004059 degradation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 230000000368 destabilizing Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 102000037240 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 201000002406 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 108010017007 glucose-regulated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 230000003067 hemagglutinative Effects 0.000 description 1
- 230000000493 homozygosity Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl radical Chemical class [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000016178 immune complex formation Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002055 immunohistochemical Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 230000000415 inactivating Effects 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 101700052395 ire-1 Proteins 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710017890 large T Proteins 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 108010031099 mannose receptor Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000020654 modulation by virus of host translation Effects 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000000663 muscle cells Anatomy 0.000 description 1
- 230000000869 mutational Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000004816 paper chromatography Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- 229930001140 podophyllotoxin Natural products 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000032029 positive regulation of DNA repair Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- ZDWVWKDAWBGPDN-UHFFFAOYSA-O propidium Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 ZDWVWKDAWBGPDN-UHFFFAOYSA-O 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000009163 protein therapy Methods 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000003439 radiotherapeutic Effects 0.000 description 1
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 1
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000034408 response to ionizing radiation Effects 0.000 description 1
- 108091007521 restriction endonucleases Proteins 0.000 description 1
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 230000001340 slower Effects 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000001360 synchronised Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 108060008606 traP Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Definitions
- the present invention relates generally to the fields of cancer therapy and control of cell proliferation. More particularly, it concerns the use of the c-Abl and p300 genes, either alone or in combination with p53, to induce programmed cell death or decreased cell proliferation.
- Certain cancer treatment methods involve damaging the DNA of the cancer cell.
- the cellular response to DNA damage includes activation of DNA repair, cell cycle arrest and lethality (Hall, 1988).
- the signaling events responsible for the regulation of these events remain unclear.
- EGR early growth response
- Mitomycin C is an antitumor antibiotic isolated from Streptomyces caespitosus that covalently binds to DNA (Tomasz et al, 1988) This agent induces both monofunctional and bifunctional DNA lesions (Carrano et al, 1979) Other studies have demonstrated that MMC stimulates the formation of hydroxyl radicals (Dusre et al, 1989) Although the precise mechanism of action of this agent is unclear, MMC-induced cytotoxicity has been attributed to DNA alkylation and the formation of interstrand cross-links (Carrano et al. , 1979, Dusre et al. , 1989, Tomasz et al.
- Protein tyrosine kinases can be divided into receptor-type and nonreceptor- type (Src-like) kinases (Cantley et al, 1991; Hanks et al, 1988; Bonni et al, 1993; Larner et al, 1993; Ruff- Jamison et al, 1993).
- Several protein tyrosine kinases have been purified from the cytosolic fractions of various tissues (Nakamura et al, 1988; Wong & Goldberg, 1984;
- the Src-like kinases which can associate with receptors at the plasma membrane, induce rapid tyrosine phosphorylation and/or activation of effectors such as phospholipase C- ⁇ l (PLC ⁇ l) (Carter et al, 1991), PLC ⁇ 2 (Hempel et al, 1992), mitogen-activated protein
- MAP MAP kinase
- GAP GTPase activating protein
- PI3-K phosphatidylinositol 3 -kinase
- the present invention in one embodiment, provides a method for increasing p53-mediated apoptosis in a tumor cell comprising the step of increasing the activity level of at least one of c-Abl and p300 in said tumor cell.
- the tumor cell may be derived from various tissues including brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue
- the activity levels of both c-Abl and p300 are increased in said tumor cell
- Increasing activities may be accomplished (i) by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor cell in an amount effective to increase p53-mediated apoptosis, (ii) by providing at least one of a nucleic acid encoding c-Abl and a nucleic acid encoding p300 to said tumor cell, wherein said nucleic acid is operably linked to a promoter active in eukaryotic cells in an amount effective to increase p53-mediated apoptosis, or (iii) by providing an agent to said cell that increases the expression or stability of at least one of c-Abl and p300 in an amount effective to increase p53-mediated apoptosis
- nucleic acids contained in viral expression vectors, via infection of target cells by encapsulated viral vectors also is contemplated
- viral vectors include herpesvirus, adenovirus, vaccinia virus, retrovirus and adeno-associated virus
- the method may further comprise determining the p53 activity of the target cell Where the target cell is defective in p53, and the method further comprises providing to said tumor cell a nucleic acid encoding a wild-type p53 operably linked to a promoter active in eukaryotic cells
- the p53 nucleic acid preferably is contained in an expression vector, and more preferably in a viral vector
- target cells may be subjected, either before or after the methods described above, to ionizing radiation or to a chemotherapeutic agent
- the ionizing radiation may be x-irradiation or ⁇ -irradiation
- the chemotherapeutic agent may be mitomycin C, etoposide, genistin, cisplatin, 5-FU, adriamycin, doxorubicin, actinomycin D, verapamil, nitrosourea, ara-C and camptothecin
- a method for treating a patient having a tumor comprising the step of increasing the activity level of at least one of c-Abl and p300 in cells of said tumor Again, the activity level may be increased by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor in an amount effective to increase p53-mediated apoptosis in cells thereof
- the method may further comprising screening the tumor cells to determine the p53 status thereof
- the method may further comprise providing to said tumor cells a nucleic acid encoding a wild-type p53 operably linked to a promoter active in eukaryotic cells
- the method may further take advantage of combined therapies, for example, by additionally treating the tumor with ionizing radiation or a chemotherapeutic agent
- a method of screening a candidate substance for p53 -stimulatory activity comprising the steps of (i) providing a eukaryotic cell expressing a functional p300 polypeptide, (ii) contacting said cell with said candidate substance, and (iii) determining the effect of said candidate substance on the p300 level of said cell, wherein an increase in the p300 level in said cell, as compared to an untreated cell, indicates that said candidate substance increases p53 activity
- a similar method is provided where the effect of the candidate substance on c-Abl is determined
- the p300 or c-Abl level may be measured by Western blot or ELISA
- contacting comprises transferring said nucleic acid into said cell
- Methods of transferring include transfection, lipofection, protoplast fusion, bombardment, electroporation or viral infection
- a use of at least one of a p300 and a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase p53-mediated apoptosis in a cell (ii) a use of at least one of a nucleic acid encoding a p300 polypeptide and a nucleic acid encoding a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase apoptosis in a cell, (iii) a use of a p300 polypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer, and (iv) a use of a p300 polypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer
- kits for use in killing malignant cells or reducing their growth are kits for use in cancer treatment
- the kits of the invention will generally comprise, in suitable container means, pharmaceutical formulations of a p53 polypeptides or gene construct, c-Abl polypeptides or gene constructs and p300 polypeptides or gene constructs
- p53 polypeptides or gene construct a p53 polypeptides or gene construct
- c-Abl polypeptides or gene constructs p300 polypeptides or gene constructs
- kits for use in killing malignant cells or reducing their growth will generally comprise, in suitable container means, pharmaceutical formulations of a p53 polypeptides or gene construct, c-Abl polypeptides or gene constructs and p300 polypeptides or gene constructs
- These agents may be present within a single container, or these components may be provided in distinct or separate container means
- Classical chemotherapeutic pharmaceutical preparations also are contemplated for use with the therapeutic compositions of the present invention
- FIGS. lA-C Overexpression of kinase active c-Abl downregulates Cdk activity
- FIG 1A MCF-7 cells were transfected with 2 ⁇ g p53-enhancer-luciferase plasmid (mdm2NA-Luc) and, (1) 8 ⁇ g control vector pSRaMSVtkNeo, (2) 5 and 8 ⁇ g c-abl vector, (3) 5 and 8 ⁇ g c-Aabl (K-R) vector, and (4) 5 and 8 ⁇ g c-abl ⁇ Pro 4 vector
- Cells were also transfected with 2 ⁇ g SV40-promoter-luciferase plasmid (pGL2-control vector, Promega) and 8 ⁇ g c-Abl vector Luciferase activity was measured and normalized for protein concentration to that for control vector, D, MCF-7 cells were transfected with 8 ⁇ g control, c-abl, c-abl (K-R) of c-abl ⁇
- FIGS. 2A-D c-Abl kinase activity regulates irradiation (IR)-induced inhibition of Cdk2
- FIG 2A MCF-7 cells stably transfected with null pSR vector or c-abl (K-R) were treated with 5 Gy IR and collected after 3h Nuclei were isolated and nuclear proteins immunoprecipitated with anti-Abl (Ab-3, Oncogene Science) as described Immune- complex kinase was analyzed using a glutathione S transferase (GST)-Crk (120-225) fusion protein as substrate (top) And Abl immunoprecipitates were also analyzed by immunoblotting with anti-Abl (bottom)
- FIG 2B Lysates were immunoblotted with anti- Abl, anti-p53 (Ab-6, Oncogene Science), anti-p21, anti-GADD45 (AT-26, Santa Cruz Biotechnology) and anti-c-Myc (9E10, Santa Cruz Biotechnology)
- FIG 2C Lys
- FIGS. 3A-D c-Abl kinase activity regulates IR-induced growth arrest
- FIG 3 A Representative two-dimensional FACS analysis of MCF-7/pSR and MCF-7/c-Abl (K-R) cells after exposure to 0 or 5 Gy IR Synchronized cells were irradiated and percentage of cells in S phase was assessed at 24h Boxes labeled Rl, R2 and R3 represent S, Gl and G2/M phase cells, respectively
- FIG 3B Percentage of cells entering S phase after IR relative to control unirradiated cells Results are expressed as the mean ⁇ s e of 6 experiments for each of two (a,b) independently selected clones
- FIG 3C C57BL6 wild- type (ab h ) and abl' MEFs were exposed to 0 or 5 Gy and collected at 3 h Cell lysates were immunoblotted with anti-Abl and anti-PCNA antibodies
- FIGS. 4A-D c-Abl kinase downregulates Cdk2 activity by a p53-dependent. p21 -independent mechanism
- FIG 4A Lysates were immunoprecipitated with anti-Abl (left) or anti-p53 (right) and the precipitates analyzed by immunoblotting with the indicated antibodies
- FIG 4B MEFs (p59 7 , p53 +/+ ) n were transfected with the c-abl or c-abl (K-R) vectors and collected at 48 h
- FIG 4C MEFs (abt' ab ' ) 11 were exposed to D or 5 Gy and collected at the indicated times
- FIG 4D MEFs (p2T , p21 +/+ were transfected with the c-Abl or c-Abl (K-R) vectors and collected at 48 h
- Cell lysates were immunoprecipitated with anti-Cdk2 and the precipitates assayed for histone HI
- the c-Abl protein tyrosine kinase is activated by certain DNA-damaging agents, and its overexpression causes arrest in the Gl phase of the cell cycle by the tumor- suppressor protein p53 (Sawyers et al, 1994, Mattioni et al., 1995, Goga et al, 1995)
- the present investigators studied the role of c-Abl in growth arrest induced by DNA damage Transient transfection experiments using wild-type or inactivated c-Abl show that both induce expression of p21, an effector of p53, but only wild-type c-Abl down regulates the activity of the cyclin-dependent kinase Cdk2 and causes growth arrest
- Exposure to ionizing radiation of cells that stably express active or inactive c-Abl is associated with induction of c-Abl/p53 complexes and p21 expression.
- cells expressing the dominant-negative c-Abl mutant and cells lacking the c-abl gene are impaired in their ability to down-regulate Cdk2 or undergo Gl arrest in response to ionizing radiation.
- p300 is a nuclear protein originally identified for its ability to interact with adenovirus El A protein It is a regulator of transcription and interacts with a variety of cellular as well as viral proteins p300 possesses histone acetyltransferase activity resulting from either intrinsic activity and/or from an assocaited protein, P/CAF Bannister et al, 1996, Ogryzko et al, 1996, Yang et al, 1996 The acetylation of histones in thought to be involved in destabilization and restructuring of nucleosomes, which is likely a crucial event for accessibility of transcription factors to DNA templates
- p300 A role for p300 in control of cellular growth has been proposed on the basis of the functional behavior of adenovirus El A and SV40 Tag proteins, which lose the ability to bind p300 Moran, 1993, Avantaggiati et al, 1996, Eckner et al, 1996a Such mutants are defective in the induction of cellular DNA synthesis and, in several instances, of transformation
- p300 is required for the activation of muscle-specific genes and for cell cycle arrest during differentiation of muscle cells. Eckner et al, 1996b, Puri et al, 1997.
- mutations or translocation of the p300 gene has been described in human tumors.
- p300 mutations in colorectal carcinomas are somatic and coupled to deletion of the second allele of the gene, suggesting that p300 is consequently inactivated It also is induced upon a cell's exposure to radiation On the basis of this evidence, p300 is envisioned to be a negative regulator of cell growth
- p300 apparently is responsible for several p53-mediated functions, such as inhibition of API -regulated enhancers, transcriptional activation, apoptosis and cell cycle progression
- the present inventors have determined that p300 is activated by c-Abl More specifically, p300 is phosphorylated by a tyrosine kinase function of c-Abl This phosphorylation causes p300 interaction with p53, and the aforementioned activities
- the present invention exploits signaling pathways that are involved in the correction of DNA damage, in cell cycle progression and in apoptosis
- the methods involve the use of the c-Abl, p300 and p53 gene products to effect cellular responses to various external stimuli
- the present invention provides a means of increasing the levels of wild-type p53 expression in tumor cells, thereby allowing for an increased apoptosis or reduction in cellular proliferation
- c-Abl and p300 can increase the expression of wild-type p53
- cancers that express normal p53 can be treated with c-Abl genes or the c-Abl gene product, or with p300 or the corresponding p300 gene
- the compositions of the present invention can be used to augment conventional gene therapy, where wild- type p53 is introduced into tumor cells concomitantly with c-Abl and/or p300 to increase the level of p53 so that programmed cell death is triggered
- the present application is drawn, in one embodiment, to methods of screening cells for their ability to express wild-type p53 protein expression of cancer cells and to concomitantly induce apoptosis in said cells
- To augment the expression of p53 one would then add the c-Abl gene product and/or p300 to a cell If wild-type p53 is lacking in a cell, wild-type p53 and c-Abl are administered to a cell in combination to induce the apoptotic response
- Effective amounts are those amounts of compositions effective at reproducibly increasing wild-type p53 expression in cancer cells in comparison to their normal levels Compounds that achieve significant appropriate changes in activity will be used A significant increase in wild-type p53 expression, e.g., as measured using for example,
- Western blot analysis are represented by an increase in wild-type p53 levels of at least about 30%-40%, and most preferably, by increases of at least about 50%, with higher values of course being possible Assays that measure p53 content and expression in cells are well known in the art and may be conducted in vitro or in vivo
- MTT assay it may be desirable simply to measure inhibition of growth of cancer cells, for example, by measuring growth according to the MTT assay
- a significant inhibition in growth is represented by decreases of at least about 30%-40% as compared to uninhibited, and most preferably, of at least about 50%, with more significant decreases also being possible.
- Growth assays as measured by the MTT assay are well known in the art Assays may be conducted as described by Mosmann et al, 1983; Rubinstein et al, 1990 (incorporated herein by reference) Therefore, if a candidate substance exhibited inhibition of growth of cancer cells in this type of study, it would likely be a suitable compound for use in the present invention.
- vectors that incorporate nucleic acid sequences that encode the c-Abl and p300 sequences It is contemplated that these vectors may either be transiently incorporated into the host cell, or may be stably integrated into the host cell genome This expression preferably occurs in a mammalian cell, and even more preferably, the mammalian cell is a human cell.
- suitable vectors for use within the scope of the present invention include, but are not limited to, adenovirus, adeno-associated virus, retrovirus or herpes simplex virus 1.
- the present invention contemplates the preparation of nucleic acid molecules that comprise a coding region that contains regions complementary to and capable of hybridizing with a c-Abl gene sequence.
- the preferred nucleic acid molecules will be DNA sequences arranged in a vector, such as a virus or plasmid, and positioned under the control of an appropriate promoter.
- the antisense RNA molecule may itself be an appropriate nucleic acid, such as retrovirus RNA into which the appropriate coding sequences have been incorporated.
- the nucleic acids may be introduced into cells by means of liposomes, or the like.
- a target cell with a c-Abl and/or p300 construct in a combined amount effective to kill the cell. This process may involve contacting the cells with the p53 construct and c-Abl/p300 construct(s) at the same time.
- compositions or pharmacological formulations that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the p53 construct and the other composition includes the c-Abl construct
- target cell where lacking a functional p53 molecule, may be first exposed to a p53 expression construct and then contacted with a c-Abl or p300 construct, or vice versa
- contacted and “exposed”, when applied to a cell are used herein to describe the process by which a p53 or c-Abl construct are delivered to a target cell or are placed in direct juxtaposition with the target cell
- either one or both agents are delivered to a cell in a combined amount effective to kill the cell, i.e , to induce programmed cell death or apoptosis
- killing i.e , to induce programmed cell death or apoptosis
- apoptosis are used interchangeably in the present text to describe a series of intracellular events that lead to target cell death Reduced cell growth refers to a lower rate of cellular proliferation than observed for the untreated cells
- p53 As a Tumor Suppressor p53 is currently recognized as a tumor suppressor gene (Montenarh, 1992) High levels have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40 The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992) It is mutated in over 50% of human NSCLC (Hollestein et al, 1991) and in a wide spectrum of other tumors
- the p53 gene encodes a 393-amino-acid phosphoprotein that can form complexes with host proteins such as large-T antigen and E1B
- the protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue Interestingly, wild-type p53 appears to be important in regulating cell growth and division Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines Thus p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or indirectly activate genes that suppress this growth Thus, absence or inactivation of wild type p53 may contribute to transformation However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene
- Wild-type p53 is recognized as an important growth regulator in many cell types Mis-sense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene
- a single genetic change prompted by point mutations can create carcinogenic p53 Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991)
- a patient presenting a p53-positive tumor that expresses wild-type p53 will be treated with c-Abl and/or p300 based therapies
- the p53 status of the tumor cells will be determined using any conventional methods, examples of which are described below
- Patients may, but need not, have received previous chemo-, radio- or gene therapies
- patients will have adequate bone marrow function (defined as peripheral absolute granulocyte count of > 2,000/mm 3 and platelet count of 100,000/mm 3 ), adequate liver function (bilirubin ⁇ 1 5 mg/dl) and adequate renal function (creatinine ⁇ 1 5 mg/dl)
- the patient will be treated with a pharmaceutically acceptable form of the c-Abl and/or p300 gene products, or will be treated by gene therapy techniques that will allow the in vivo expression of the c-Abl or p300 gene products Alternatively, the patient may be treated with a substance that augments the expressionon c-Abl or p300 normally produced by the target cell Treatment regimens normally last between about 3 and 6 weeks, and involve repeat dosings In order to know whether a cell will respond to provision of c-Abl and/or p300, it must first be determined whether the cell expresses an active p53 molecule Thus, screening for p53 expression is an important first step
- detection methods can be employed in the present invention to detect the p53 status of a cell
- any assay that utilizes antibodies for detection for example, ELISAs, Western Blotting, immunoassay techniques etc
- assays that employ nucleotide probes may be used to identify the presence/absence/status of p53, for example, Southern blotting,
- Immunoassays encompassed by the present invention include, but are not limited to those described in U S Patent No 4,367,110 (double monoclonal antibody sandwich assay) and U S Patent No 4,452,901 (Western blot) Other assays include immunoprecipitation of labeled ligands and immunocytochemistry, both in vitro and in vivo
- Immunoassays in their most simple and direct sense, are binding assays. Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art Immunohistochemical detection using tissue sections is also particularly useful.
- ELISAs enzyme linked immunosorbent assays
- RIA radioimmunoassays
- anti-p53 antibodies are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate Then, a test composition suspected of containing the desired antigen, such as a clinical sample, is added to the wells After binding and washing to remove non-specifically bound immune complexes, the bound antigen may be detected Detection is generally achieved by the addition of another antibody, specific for the desired antigen, that is linked to a detectable label This type of ELISA is a simple "sandwich ELISA" Detection may also be achieved by the addition of a second antibody specific for the desired antigen, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label
- Varaitions of ELISA techniques are know to those of skill in the art
- the samples suspected of containing the desired antigen are immobilized onto the well surface and then contacted with the antibodies of the invention After binding and appropriate washing, the bound immune complexes are detected
- the immune complexes may be detected directly
- the immune complexes may be detected using a second antibody that has binding affinity for the first antigen specific antibody, with the second antibody being linked to a detectable label
- Competition ELISAs are also possible in which test samples compete for binding with known amounts of labeled antigens or antibodies
- the amount of reactive species in the unknown sample is determined by mixing the sample with the known labeled species before or during incubation ⁇ with coated wells
- the presence of reactive species in the sample acts to reduce the amount of labeled species available for binding to the well and thus reduces the ultimate signal
- ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes These are described as below
- Antigen or antibodies may also be linked to a solid support, such as in the form of plate, beads, dipstick, membrane or column matrix, and the sample to be analyzed applied to the immobilized antigen or antibody
- a solid support such as in the form of plate, beads, dipstick, membrane or column matrix
- the sample to be analyzed applied to the immobilized antigen or antibody
- a plate with either antigen or antibody one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period The wells of the plate will then be washed to remove incompletely adsorbed material Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera These include bovine serum albumin (BSA), casein and solutions of milk powder
- BSA bovine serum albumin
- casein casein
- the coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of anti
- the immobilizing surface is contacted with the clinical or biological sample to be tested under conditions effective to allow immune complex
- Under conditions effective to allow immune complex (antigen/antibody) formation means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate buffered saline (PBS)/Tween These added agents also tend to assist in the reduction of nonspecific background
- the suitable conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding Incubation steps are typically from about 1 to 2 to 4 hours, at temperatures preferably on the order of 25° to 27°C, or may be overnight at about 4°C or so
- washing often includes washing with a solution of
- the second or third antibody will have an associated label to allow detection
- this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate
- a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex formation, e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween.
- the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H 2 O , in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer
- the label may be a chemiluminescent one.
- Assays for the p53 radiation status of the cell can determine normal/abnormal tissue distribution for diagnostic purposes
- Methods for in vitro and in situ analysis are well known and involve assessing binding of antigen-specific antibodies to tissues, cells or cell extracts These are conventional techniques well within the grasp of those skilled in the art
- the antibodies to p53 may be used in conjunction with both fresh-frozen and formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC) Each tissue block may consist of 50 mg of residual "pulverized" tumor
- IHC immunohistochemistry
- frozen-sections may be prepared by rehydrating 50 ng of frozen pulverized tumor at room temperature in PBS in small plastic capsules, pelleting the particles by centrifugation, resuspending them in a viscous embedding medium (OCT), inverting the capsule and pelleting again by centrifugation, snap-freezing in -70°C isopentane, cutting the plastic capsule and removing the frozen cylinder of tissue, securing the tissue cylinder on a cryostat microtome chuck, and cutting 25-50 serial sections containing an average of about 500 remarkably intact tumor cells
- OCT viscous embedding medium
- Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube, pelleting, resuspending in 10% formalin for 4 hours fixation, washing/pelleting; resuspending in warm 2 5% agar, pelleting, cooling in ice water to harden the agar; removing the tissue/agar block from the tube, infiltrating and embedding the block in paraffin, and cutting up to 50 serial permanent sections
- nucleic acids may be isolated from cells according to standard methodologies (Sambrook et al, 1989)
- the nucleic acid may be genomic DNA or fractionated or whole cell RNA Where mRNA is used, it may be desired to convert the mRNA to a complementary DNA
- the RNA is whole cell RNA, in another, it is poly-A RNA Normally, the nucleic acid is amplified
- the specific nucleic acid of interest is identified in the sample directly using amplification or with a second, known nucleic acid following amplification
- the identified product is detected
- the detection may be performed by visual means (e.g., ethidium bromide staining of a gel)
- the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals
- alterations should be read as including deletions, insertions, point mutations and duplications
- Point mutations result in stop codons, frameshift mutations or amino acid substitutions
- Somatic mutations are those occurring in non-germline tissues
- Germ-line tissue can occur in any tissue and are inherited Mutations in and outside the coding region also may affect the amount of p53 produced, both by altering the transcription of the gene or in destabilizing or otherwise altering the processing of either the transcript (mRNA) or protein
- FISH fluorescent in situ hybridization
- PFGE direct DNA sequencing
- SSCA single-stranded conformation analysis
- ASO allele-specific oligonucleotide
- dot blot analysis denaturing gradient gel electrophoresis, RFLP and PCR-SSCP
- primer as defined herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process
- primers are oligonucleotides from ten to twenty base pairs in length, but longer sequences can be employed
- Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred
- Probes are defined differently, although they may act as primers
- Probes while perhaps capable of priming, are designed to binding to the target DNA or RNA and need not be used in an amplification process
- the probes or primers are labeled with radioactive species ( 32 P, 14 C, 35 S, 3 H, or other label), with a fluorophore (rhodamine, fluorescein) or a chemillumiscent (luciferase)
- radioactive species 32 P, 14 C, 35 S, 3 H, or other label
- fluorophore rhodamine, fluorescein
- chemillumiscent luciferase
- PCRTM polymerase chain reaction
- PCR two primer sequences are prepared that are complementary to regions on opposite complementary strands of the marker sequence
- An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase, e.g. , Taq polymerase
- a DNA polymerase e.g. , Taq polymerase
- the primers will bind to the marker and the polymerase will cause the primers to be extended along the marker sequence by adding on nucleotides
- the extended primers will dissociate from the marker to form reaction products, excess primers will bind to the marker and to the reaction products and the process is repeated
- a reverse transcriptase PCR amplification procedure may be performed in order to quantify the amount of mRNA amplified
- Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al, 1989
- Alternative methods for reverse transcription utilize thermostable, RNA-dependent DNA polymerases These methods are described in WO 90/07641 filed December 21, 1990 Polymerase chain reaction methodologies are well known in the art
- LCR ligase chain reaction
- Qbeta Replicase described in PCT Application No PCT US87/00880, may also be used as still another amplification method in the present invention
- a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase The polymerase will copy the replicative sequence that can then be detected
- restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha- thio]-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention, Walker et al, (1992)
- SDA Strand Displacement Amplification
- RCR cyclic probe reaction
- DNA and a middle sequence of specific RNA is hybridized to DNA that is present in a sample Upon hybridization, the reaction is treated with RNase H, and the products of the probe identified as distinctive products that are released after digestion The original template is annealed to another cycling probe and the reaction is repeated Still another amplification methods described in GB Application No 2 202 328, and in PCT Application No PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention In the former application, "modified" primers are used in a PCR-like, template- and enzyme- dependent synthesis The primers may be modified by labeling with a capture moiety
- an excess of labeled probes are added to a sample
- the probe binds and is cleaved catalytically After cleavage, the target sequence is released intact to be bound by excess probe Cleavage of the labeled probe signals the presence of the target sequence
- nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Kwoh et al, 1989, Gingeras et al, PCT Application WO 88/10315, incorporated herein by reference in their entirety)
- TAS transcription-based amplification systems
- NASBA nucleic acid sequence based amplification
- 3SR 3SR
- the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA
- amplification techniques involve annealing a primer which has target specific sequences Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded
- DNA molecules are heat denatured again In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization
- the double-stranded DNA molecules are then multiply transcribed by an RNA polymerase such as T7 or SP6 In an isothermal cyclic reaction, the RNA's are reverse transcribed into single stranded DNA, which is then converted to double stranded
- RNA polymerase such as T7 or SP6
- ssRNA single- stranded RNA
- dsDNA double-stranded DNA
- the ssRNA is a template for a first primer oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase)
- RNA-dependent DNA polymerase reverse transcriptase
- the RNA is then removed from the resulting DNA RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA)
- RNase H an RNase specific for RNA in duplex with either DNA or RNA
- the resultant ssDNA is a template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to the template This primer is then extended by DNA polymerase (exemplified by the large "K
- dsDNA double-stranded DNA
- dsDNA double-stranded DNA
- This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA These copies can then re-enter the cycle leading to very swift amplification With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA
- a probe is used to target a DNA or RNA species that has been immobilized on a suitable matrix, often a filter of nitrocellulose
- the different species should be spatially separated to facilitate analysis This often is accomplished by gel electrophoresis of nucleic acid species followed by "blotting" on to the filter
- the blotted target is incubated with a probe (usually labeled) under conditions that promote denaturation and rehybridization Because the probe is designed to base pair with the target, the probe will binding a portion of the target sequence under renaturing conditions Unbound probe is then removed, and detection is accomplished as described above
- amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods See Sambrook et al, 1989
- chromatographic techniques may be employed to effect separation
- adsorption, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography
- Products may be visualized in order to confirm amplification of the marker sequences
- One typical visualization method involves staining of a gel with ethidium bromide and visualization under UV light
- the amplification products can then be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation
- ⁇ visualization is achieved indirectly
- a labeled nucleic acid probe is brought into contact with the amplified marker sequence
- the probe preferably is conjugated to a chromophore but may be radiolabeled
- the probe is conjugated to a binding partner, such as an antibody or biotin, and the other member of the binding pair carries a detectable moiety
- detection is by a labeled probe
- chromophore or radiolabel probes or primers identify the target during or following amplification
- oligonucleotide primers may be designed to permit the amplification of sequences throughout the p53 gene that may then be analyzed by direct sequencing
- kits This generally will comprise preselected primers and probes Also included may be enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, SequenaseTM, etc ), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification
- enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, SequenaseTM, etc ), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification
- kits also generally will comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each primer or probe
- chip-based DNA technologies such as those described by Hacia et al. (1996) and Shoemaker et al. (1996)
- a c-Abl and optionally or alternatively, p300 polypeptide or a gene construct that comprises a c-Abl sequence, and optionally or alternatively, a p300 sequence are used in combination with a recombinant vector that comprises a nucleic acid sequence capable of expressing the desired gene sequence in the cell.
- the vector typically is introduced into the cell in a manner that allows expression of the encoded gene sequence at a level sufficient to effect cell function and cause an apoptotic response or to reduce cell proliferation.
- expression construct is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed
- the transcript may be translated into a protein, but it need not be
- expression includes both transcription of a p53, p300 or c-Abl gene and translation of p53, p300 or c-Abl mRNA into the proper protein product
- promoter refers to a DNA sequence recognized by the synthetic machinery of the host cell, or introduced synthetic machinery, that is required to initiate the specific transcription of a gene
- under transcriptional control means that the promoter is in the correct location in relation to the polynucleotide to control RNA polymerase initiation and expression of the polynucleotide
- promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II
- Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units
- At least one module in each promoter functions to position the start site for RNA synthesis
- the best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation
- promoter elements regulate the frequency of transcriptional initiation Typically, these are located in the region 30-1 10 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well
- the spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another
- the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription
- the particular promoter that is employed to control the expression of ap53 or c- Abl polynucleotide is not believed to be critical, so long as it is capable of expressing the polynucleotide in the targeted cell
- a promoter that is capable of being expressed in a human cell
- such a promoter might include either a human or viral promoter
- the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of the p53 or c-Abl polynucleotide
- CMV cytomegalovirus
- the use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of polynucleotides is contemplated as well, provided that the levels of expression are sufficient to produce a growth inhibitory effect
- a promoter which is active in specific cells, such as tyrosinase (melanoma), alpha-fetoprotein and albumin (liver tumors), CC10 (lung tumor) and prostate-specific antigen (prostate tumor) will permit tissue-specific expression of p53 or c-Abl constructs
- Table 1 lists several elements/promoters which may be employed, in the context of the present invention, to regulate the expression o ⁇ p53 or c-Abl constructs This list is not intended to be exhaustive of all the possible elements involved in the promotion of p53 or c-Abl expression but, merely, to be exemplary thereof
- Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins
- enhancers are operational An enhancer region as a whole must be able to stimulate transcription at a distance, this need not be true of a promoter region or its component elements On the other hand, a promoter must have one or. more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization
- Eukaryotic Promoter Data Base EPDB any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a p53, p300 or c-Abl construct
- a T3, T7 or SP6 cytoplasmic expression system Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment Eukaryotic cells can support cytoplasmic transcription from certain bacteriophage promoters if the appropriate bacteriophage polymerase is provided, either as part of the delivery complex or as an additional genetic expression vector
- NCAM Neural Cell Adhesion Molecule
- SAA Human Serum Amyloid A
- a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the p53 construct.
- expression is inducible by tumor necrosis factor.
- Table 2 illustrates several promoter/inducer combinations:
- the delivery of an expression vector in a cell may be identified in vitro or in vivo by including a marker in the expression vector
- the marker would result in an identifiable change to the transfected cell permitting easy identification of expression
- a drug selection marker aids in cloning and in the selection of transformants
- enzymes such as herpes simplex virus thymidine kinase (tk) (eukaryotic) or chloramphenicol acetyltransferase (CAT) (prokaryotic)
- CAT chloramphenicol acetyltransferase
- Immunologic markers also can be employed
- the selectable marker employed is not believed to be important, so long as it is capable of being expressed along with the polynucleotide encoding p53 Further examples of selectable markers are well known to one of skill in the art
- polyadenylation signal to effect proper polyadenylation of the transcript
- the nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed
- the inventor has employed the SV40 polyadenylation signal in that it was convenient and known to function well in the target cells employed Also contemplated as an element of the expression construct is a terminator These elements can serve to enhance message levels and to minimize read through from the construct into other sequences
- the cells contain nucleic acid constructs of the present invention
- a cell may be identified in vitro or in vivo by including a marker in the expression construct
- markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct
- a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers
- enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be employed
- Immunologic markers also can be employed The selectable marker employed is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product Further examples of selectable markers are well known to one of skill in the art
- IRES elements internal ribosome binding sites
- IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites
- IRES elements from two members of the picanovirus family polio and encephalomyocarditis
- IRES elements from two members of the picanovirus family Polio and encephalomyocarditis
- IRES elements can be linked to heterologous open reading frames
- Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages
- each open reading frame is accessible to ribosomes for efficient translation
- Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message
- Any heterologous open reading frame can be linked to IRES elements This includes genes for secreted proteins, multi-subunit proteins, encoded by independent genes, intracellular or membrane-bound proteins and selectable markers In this way, expression of several proteins can be simultaneously engineered into a cell with a single construct and a single selectable marker
- the expression construct comprises a virus or engineered construct derived from a viral genome
- a virus or engineered construct derived from a viral genome
- expression vectors need not be viral but, instead, may be any plasmid, cosmid or phage construct that is capable of supporting expression of encoded genes in mammalian cells, such as pUC or BluescriptTM plasmid series
- the retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990)
- the resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins
- the integration results in the retention of the viral gene sequences in the recipient cell and its descendants
- the retroviral genome contains three genes - gag, pol, and env - that code for capsid proteins, polymerase enzyme, and envelope components, respectively
- a sequence found upstream from the gag gene, termed ⁇ functions as a signal for packaging of the genome into virions
- Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990)
- a nucleic acid encoding a p53 is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective
- a packaging cell line containing the gag, pol and env genes but without the LTR and ⁇ components is constructed (Mann et al, 1983)
- the ⁇ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988, Temin, 1986, Mann et al, 1983)
- the media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer Retroviral vectors are able to infect a broad variety of cell types
- Retroviral vectors are able to infect a broad variety of cell types
- adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb (Tooza, 1981)
- adenoviruses As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system
- This group of viruses is easy to grow and manipulate, and exhibit a broad host range in vitro and in vivo
- adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus
- the El region of the genome includes El A and E1B which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular genes E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, e.g. DNA-binding protein, DNA polymerase, and a terminal protein that primes replication E3 gene products prevent cytolysis by cytotoxic T cells and tumor necrosis factor and appear to be important for viral propagation Functions associated with the E4 proteins include DNA replication, late gene expression, and host cell shutoff
- the late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred
- the major late promoter exhibits high efficiency during the late phase of the infection (Stratford-Perricaudet and Perricaudet, 1991)
- adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells
- Ad 5 -transformed human embryonic kidney cell lines have been developed to provide the essential viral proteins in trans. The inventor thus reasoned that the characteristics of adenoviruses rendered them good candidates for use in targeting cancer cells in vivo (Grunhaus & Horwitz, 1992)
- an adenovirus system for delivering foreign proteins to a cell include (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA, (ii) the structural stability of recombinant adenoviruses, (iii) the safety of adenoviral administration to humans, £nd (iv) lack of any known association of adenoviral infection with cancer or malignancies, (v) the ability to obtain high titers of the recombinant virus, and (vi) the high infectivity of Adenovirus
- adenovirus vectors over retroviruses include the higher levels of gene expression Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences Because adenovirus transforming genes in the El region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible (Grunhaus & Horwitz, 1992)
- adenovirus gene transfer systems are based upon recombinant, engineered adenovirus which is rendered replication-incompetent by deletion of a portion of its genome, such as El, and yet still retains its competency for infection Sequences encoding relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome For example, adenoviruses deleted in both El and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293 cells (Stratford-Perricaudet and Perricaudet, 1991) Surprisingly persistent expression of transgenes following adenoviral infection has also been reported
- Adenovirus-mediated gene transfer has recently been investigated as a means of mediating gene transfer into eukaryotic cells and into whole animals
- OTC rare recessive genetic disorder ornithine transcarbamylase
- viral vectors may be employed as expression constructs in the present invention.
- Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpes viruses may be employed. These viruses offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden,
- CAT chloramphenicol acetyltransferase
- the expression vector In order to effect expression of therapeutic constructs according to the present invention, the expression vector must be delivered into a cell As described above, one mechanism for delivery is via viral infection where the expression vector is encapsidated in an infectious virus particle
- Another embodiment of the invention for transferring a naked DNA expression vector into cells may involve particle bombardment This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al, 1987) Several devices for accelerating small particles have been developed One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang et al, 1990) The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads
- Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded in vivo (Yang et al, 1990, Zelenin et al, 1991) This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ DNA encoding a p53, p300 or c-Abl construct may be delivered via this method
- the expression vector may be entrapped in a liposome
- Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium Multilamellar liposomes have multiple lipid layers separated by aqueous medium Liposomes form spontaneously when phospholipids are suspended in an excess of aqueous solution The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991) Also contemplated are lipofectamine-DNA complexes
- Liposome-mediated polynucleotide delivery and expression of foreign DNA in vitro has been very successful Wong et al. (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo,
- the liposome may be complexed with a hemagglutinating virus (HVJ) This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda et al, 1989)
- the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato et al, 1991)
- HMG-1 nuclear non-histone chromosomal proteins
- the liposome may be complexed or employed in conjunction with both HVJ and HMG-1
- expression vectors have been successfully employed in transfer and expression of a polynucleotide in vitro and in vivo, then they are applicable for the present invention
- a bacteriophage promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacteriophage polymerase
- Receptor-mediated gene targeting vehicles generally consist of two components a cell receptor-specific ligand and a DNA-binding agent Several ligands have been used for receptor-mediated gene transfer The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner et al, 1993) Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol et al, 1993, Perales et al, 1994) and epidermaj growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085)
- the delivery vehicle may comprise a ligand and a liposome
- a ligand and a liposome For example, Nicolau et al. (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes
- an adenoviral expression vector also may be specifically delivered into a cell type such as lung, epithelial or tumor cells, by any number of receptor-ligand systems, with or without liposomes
- epidermal growth factor (EGF) may be used as the receptor for mediated delivery of p53, p300 or cAbl construct in many tumor cells that exhibit upregulation of EGF receptor Mannose can be used to target the mannose receptor on liver cells
- antibodies to CD 5 (CLL), CD22 (lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used as targeting moieties
- gene transfer may more easily be performed under ex vivo conditions
- Ex vivo gene therapy refers to the isolation of cells from an animal, the delivery of a polynucleotide into the cells, in vitro, and then the return of the modified cells back into an animal This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissues Anderson et al. , U S Patent 5,399,346, and incorporated herein in its entirety, disclose ex vivo therapeutic methods During ex vivo culture, the expression vector can express the p53 construct Finally, the cells may be reintroduced into the original animal, or administered into a distinct animal, in a pharmaceutically acceptable form by any of the means described below
- a patient presenting a tumor that does not express wild-type p53 will be treated with a combination of p53 and c-Abl and/or p300
- the patient will be treated with a pharmaceutically acceptable form of the c-Abl and/or p300 genes or gene products, as described above, and in addition, will be treated with a p53 gene or gene product
- a typical treatment regimen will involve repeated administrations over a six week period During this time, the tumor will be monitored for absence of tumor progression, response or toxicity and the doses adjusted accordingly
- compositions of the present invention To kill tumor cells or reduce their proliferation, using the methods and compositions of the present invention, one would generally contact a "target" cell with (i) radiation or a chemotherapeutic and (ii) a therapeutic protein or gene These compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell
- This process may involve contacting the cells with c-Abl, p300 and p53 protein or gene, at the same time This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes c-Abl protein or gene and/or p300, and the other includes the p53 protein or gene
- the protein or gene therapy treatment may precede or follow the standard chemo- or radiotherapy treatment by intervals ranging from minutes to weeks
- the other agent and an expression construct are applied separately to the cell, one generally would ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell
- both agents are delivered to a cell in a combined amount effective to kill the cell
- Agents or factors suitable for use in a combined therapy are any chemical compound or treatment method that induces DNA damage when applied to a cell
- Such agents and factors include radiation and waves that induce DNA damage such as, ⁇ -irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like
- chemotherapeutic agents function to induce DNA damage, all of which are intended to be of use in the combined treatment methods disclosed herein
- Chemotherapeutic agents contemplated to be of use include, e.g., adriamycin, 5-fluorouracil (5FU), etoposide (VP-16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP) and even hydrogen peroxide
- the invention also encompasses the use of a combination of one or more DNA damaging agents, whether radiation-based or actual compounds, such as the use of X-rays with cisplatin or the use of cisplatin with etoposide
- the use of cisplatin in combination with a c-Abl or p300 expression construct is particularly preferred as this compound
- the tumor cells In treating cancer according to the invention, one would contact the tumor cells with an agent in addition to the expression construct This may be achieved by irradiating the localized tumor site with radiation such as X-rays, UV-light, ⁇ -rays or even microwaves Alternatively, the tumor cells may be contacted with the agent by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound such as, adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, or more preferably, cisplatin
- the agent may be prepared and used as a combined therapeutic composition, or kit, by combining it with an expression construct, as described above
- Cisplatin has been widely used to treat cancer, with efficacious doses used in clinical applications of 20 mg/m 2 for 5 days every three weeks for a total of three courses Cisplatin is not absorbed orally and must therefore be delivered via injection intravenously, subcutaneously, intratumorally or intraperitoneally
- chemotherapeutic compounds include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin, and the like Widely used in a clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m 2 at 21 day intervals for adriamycin, to 35-50 mg/m 2 for etoposide intravenously or double the intravenous dose orally
- agents that have undergone extensive testing and are readily available
- agents such as 5-fluorouracil (5-FU)
- 5-FU 5-fluorouracil
- 5- FU is preferentially used by neoplastic tissue, making this agent particularly useful for targeting to neoplastic cells
- 5- FU is applicable in a wide range of carriers, including topical, however intravenous administration with doses ranging from 3 to 15 mg/kg/day being commonly used
- ⁇ -rays X-rays
- UV-irradiation UV-irradiation
- Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens
- Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells
- Aqueous compositions of the present invention will have an effective amount of a compound that increases the expression of wild-type p53, for example p300 or c-Abl gene products or p300 or c-Abl gene constructs. Such compositions will generally be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Also included in various embodiments of the present invention are standard chemotherapeutics in their various pharmaceutical forms.
- phrases "pharmaceutically or pharmacologically acceptable” refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or human, as appropriate.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in the therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-cancer agents, can also be incorporated into the compositions.
- other pharmaceutically acceptable forms include, e.g. , tablets or other solids for oral administration; time release capsules; and any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like.
- the active compounds of the present invention will often be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes.
- parenteral administration e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes.
- the preparation of an aqueous composition that contains a compound or compounds that increase the expression of wild-type p53 will be known to those of skill in the art in light of the present disclosure.
- such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared, and the preparations can also be emulsified
- compounds may be injected directly into a tumor
- the route of delivery is by a slow drip into the circulatory system of the patient
- Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms
- the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, formulations including sesame oil, peanut oil or aqueous propylene glycol, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions
- the form must be sterile and must be fluid to the extent that easy syringability exists It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi
- the active compounds may be formulated into a composition in a neutral or salt form
- Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like
- Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like
- the carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils
- a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils
- the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- the prevention of the action of microorganisms can be brought about by various antibacterial ad antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
- the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the therapeutic formulations of the invention could also be prepared in forms suitable for topical administration, such as in cremes and lotions. These forms may be used for treating skin-associated diseases, such as various sarcomas.
- solutions Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
- the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, with even drug release capsules and the like being employable.
- aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
- aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration
- sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure
- one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580)
- kits All the essential materials and reagents required for determining wild-type p53 in a sample or for increasing the expression of wild-type p53 using c-Abl and p300 in tumor cells may be assembled together in a kit
- the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being particularly preferred
- the kit may contain materials for PCR analyses, such primers, buffers and appropriate solvents Alternatively, if the detection is via immunologic means, the kit may contain antibodies directed to the p53, secondary antibodies that binding primary antibodies, labels or signal generating compounds (either conjugated or unconjugated) and various reagents for the generation and detection of signals
- an inducer of wild-type p53 expression alone or in combination with, a expression vectors may be formulated into a single or separate pharmaceutically acceptable syringeable composition
- the container means may itself be an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit
- the components of these kits may also be provided in dried or lyophilized forms When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent It is envisioned that the solvent also may be provided in another container means
- the kits of the invention may also include an instruction sheet defining administration of wild-type p53 and c-Abl gene therapy agents, or explaining the assays for determining p53 levels in samples
- kits of the present invention also will typically include a means for containing the vials in close confinement for commercial sale such as, e.g., injection or blow-molded plastic containers into which the desired vials are retained Irrespective of the number or type of containers, the kits of the invention also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal
- an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle
- Other instrumentation includes devices that permit the reading or monitoring of reactions in vitro
- c-Abl The product of the c-Abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm Ionizing radiation (IR) activates c-Abl Similar results were obtained with the alkylating agents cisplatinum and mitomycin C Cells deficient in c-Abl fail to activate Jun kinase (JNK/SAP kinase) following IR or alkylating agent exposure and that reconstitution of c-Abl in these cells restores that response In contrast, the stress response to tumor necrosis factor is stimulated by a c-Abl-independent mechanism
- c-Abl contains actin binding and DNA binding domains
- Rh retinoblastoma
- MCF-7 cells were co- transfected with a construct containing the luciferase gene driven by a p53 enhancer from the MDM2 promoter (Barak et al, 1994), and vectors expressing wild-type c-Abl, a kinase-inactive K(290)R mutant (Sawyers et al, 1994), or a kinase-active mutant, designated ⁇ Pro 4 which is deleted at the p53-binding domain (Goga et al, 1995)
- Co- transfections of the reporter with wild-type or kinase-inactive c-Abl (K-R), but not c- Abl ⁇ Pro 4 resulted in induction of luciferase activity (FIG 1A)
- c-Abl expression had no detectable effect on activation of an SV40-luciferase construct (FIG la) As transcription of p21 is regulated by
- MCF-7 cells were prepared to stably express the dominant-negative c-Abl (K-R) 2 , which effectively inhibits the increase in c-Abl kinase activity induced by ionizing radiation control cells (FIG 2A)
- Irradiation of MCF-7/pSR or MCF-7/c-Abl (K-R) cells caused an increase in p53, p21 and GADD45, but not in c-Myc (which is not dependent on p53) (FIG 2B)
- FIG 2B Irradiation of MCF-7/pSR or MCF-7/c-Abl (K-R) cells caused an increase in p53, p21 and GADD45, but not in c-Myc (which is not dependent on p53) (FIG 2B)
- FIG. 3C Wild-type MEFs after 5 Gy radiation had an S-phase population that was 45% of that for untreated cells (FIG 3D) By contrast, irradiated abl ' MEFs had more than 70%> of cells in S phase compared with controls (FIG 3D) Exposure of the wild-type and abl' ' MEFs to 20 Gy radiation partially inhibited arrest in Gl in the abl ' cells, indicating that the c-Abl kinase function is necessary for radiation-induced Gl arrest
- mutant c-Abl may prevent Gl arrest in response to DNA damage by inactivating Rb But as irradiated cells expressing c-Abl (K-R) do not arrest in Gl because Cdk2 is not inhibited, the effect probably occurs upstream of Rb
- K-R irradiated cells expressing c-Abl
- the present inventors have demonstrated that c-Abl functions in the cellular response to DNA damage through p53-dependent pathways, confirmed by the failure of the c-Abl ⁇ Pro 4 mutant to bind p53 and downregulate Cdk2 and arrest growth It has also been shown that the kinase-defective c-Abl (K-R) mutant induces p53 transactivation but no Gl arrest although
- RESULTS Cell Culture - MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (Sigma) containing 10%> heat-inactivated fetal bovine serum (Sigma), 2 mM L-glutamine, 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin Null pSR ⁇ MSVtKneo, pSR MSVc-AblK(290)-RtKNeo (Sawyers et al, 1994), or E6Neo (Scheffner et al, 1990) vectors were stably introduced into cells by LipofectAMINE (Life
- Immunoprec ⁇ itations and Immunoblot Analysis were prepared as described (Yuan et al, 1996) and incubated with rabbit anti-Cdk2 (sc-163, Santa Cruz Biotechnology, San Diego, CA), mouse anti-c-Abl (Ab-3, Oncogene Science, Cambridge, MA), mouse anti-p53 (Ab-6, Oncogene Science) antibodies for 6-12 h at 4°C and then for 60 min with protein A-Sepharose
- 10 ⁇ g/sample of rabbit anti-mouse IgG was added and incubated for 60 min before the addition of protein A beads
- the immune complexes were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose filters and analyzed by immunoblotting using an ECL (Amersham Corp ) detection system
- recombinant SHPTP1 protein 100 ⁇ g/ml was used as substrate (Kharbanda et al, 1996), and the reaction was incubated for 30 min at 30°C
- ara-C induces an interaction between c-Abl and p53 in vivo
- the inventors also prepared cells that express the human papillomavirus E6 protein to promote degradation of p53 (Scheffner et al, 1990)
- the MCF-7/E6 cells responded to ara-C with induction of c-Abl activity
- MMS exposure resulted in increased c-Abl activity in the MCF-7/pSR and MCF-7/E6 cells, but not the MCF-7/c-Abl(K-R) cells
- MMS increased binding of c-Abl and p53 in MCF-7/pSR and MCF-7/c-Abl(K-R), but not MCF-7/E6, cells
- MMS also induced the expression of p53 and p21 in only the MCF-7/pSR and MCF-7/c-Abl(K-R) cells
- the MMS-induced increases in p21 levels were associated with binding of p21 to Cdk2
- Cdk2 activity was down-regulated in MMS-treated MCF-7/pSR cells, there was little effect of MMS on Cdk2 activity in the MCF-7/c-Abl(K-R) cells
- compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.
- Gazit, A Yaish, P , etal, JMedChem, 32(10) 2344-52, 1989
- Temin "Retrovirus vectors for gene transfer Efficient integration into and expression of exogenous DNA in vertebrate cell genome," In. Kucherlapati R, ed Gene transfer
Abstract
The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with c-Abl and p300, which control levels of wild-type p53. Also included are methods of combination therapy wherein cells lacking p53 are supplemented with c-Abl, p300 and wild-type p53 to induce an apoptotic responses.
Description
DESCRIPTION
METHODS AND COMPOSITIONS FOR MODULATION OF GROWTH
RESPONSE
BACKGROUND OF THE INVENTION
The government may own rights in the present invention pursuant to grants from the National Institutes of Health.
1. Field of the Invention
The present invention relates generally to the fields of cancer therapy and control of cell proliferation. More particularly, it concerns the use of the c-Abl and p300 genes, either alone or in combination with p53, to induce programmed cell death or decreased cell proliferation.
2. Description of Related Art
Certain cancer treatment methods, including radiation therapy, involve damaging the DNA of the cancer cell. The cellular response to DNA damage includes activation of DNA repair, cell cycle arrest and lethality (Hall, 1988). The signaling events responsible for the regulation of these events, however, remain unclear.
Several checkpoints in cell cycle progression control growth in response to diverse positive and negative regulatory signals (Lau & Pardee, 1982). Ionizing radiation, for example, slows growth by inducing delays in Gj/S and G2 phases of the cell cycle. The available evidence suggests that G2 arrest in necessary for repair of DNA damage before entry into mitosis (Steinman et al, 1991; Weinert & Hartwell, 1988). Genetic studies in Saccharomyces cerevisiae have demonstrated that the RAD9 protein controls G2 arrest induced by DNA damage (Schiestl et al., 1989; Murray, 1989). Mutants of the rad9 locus are unable to delay entry into mitosis following exposure to genotoxic agents and thereby replicate damaged DNA. Although the mammalian homolog of rad9 remains unidentified, other studies in various eukaryotic cells have demonstrated that entry into mitosis is regulated by a 34 kD
serine/threonine protein kinase, designated p34cdc2 (Nurse, 1990, Pines & Hunter, 1989, Russell & Nurse, 1987)
Recent studies have shown that exposure of eukaryotic cells to ionizing radiation is associated with induction of certain early response genes that code for transcription factors
Members of the jun/fos and early growth response (EGR) gene families are activated by ionizing radiation (Sherman et al. , 1990, Datta et al. , 1992a) Expression and DNA binding of the nuclear factor kB (NF-kB) are also induced in irradiated cells (Brach etal, 1991, Uckun et al. , 1992a) Other studies have shown that levels of the tumor suppressor p53 protein increase during X-ray-induced arrest of cells in Gl phase (Kastan et al. , 1991 , 1992) The activation of these transcription factors presumably represents transduction of early nuclear signals to longer term changes in gene expression that constitute the response to irradiation
Ionizing radiation also induces protein kinase C (PKC) and protein tyrosine kinase activities (Hallahan et al, 1990, Uckun et al, 1993) However, the specific kinases responsible for these activities and their substrates require further study The interaction between radiation, cell signaling, phosphorylation and various other oncogenes and cellular protooncogenes has not been well studied to date
Mitomycin C (MMC) is an antitumor antibiotic isolated from Streptomyces caespitosus that covalently binds to DNA (Tomasz et al, 1988) This agent induces both monofunctional and bifunctional DNA lesions (Carrano et al, 1979) Other studies have demonstrated that MMC stimulates the formation of hydroxyl radicals (Dusre et al, 1989) Although the precise mechanism of action of this agent is unclear, MMC-induced cytotoxicity has been attributed to DNA alkylation and the formation of interstrand cross-links (Carrano et al. , 1979, Dusre et al. , 1989, Tomasz et al. , 1988) Treatment of mammalian cells with MMC is associated with inhibition of DNA synthesis and induction of sister-chromatid exchange (Carrano et al, 1979) Previous work has demonstrated that MMC also enhances transcription of HIV- 1 and collagenase promoter constructs transfected into HeLa cells (Stein et al, 1989) These studies indicated that AP-1 is involved in MMC-induced activation of the collagenase enhancer However, little is known about the effects of this agent on other signaling events
Protein tyrosine phosphorylation contributes to the regulation of cell growth and differentiation. Protein tyrosine kinases can be divided into receptor-type and nonreceptor- type (Src-like) kinases (Cantley et al, 1991; Hanks et al, 1988; Bonni et al, 1993; Larner et al, 1993; Ruff- Jamison et al, 1993). Several protein tyrosine kinases have been purified from the cytosolic fractions of various tissues (Nakamura et al, 1988; Wong & Goldberg, 1984;
Zioncheck et al. , 1986).
The Src-like kinases, which can associate with receptors at the plasma membrane, induce rapid tyrosine phosphorylation and/or activation of effectors such as phospholipase C- γl (PLCγl) (Carter et al, 1991), PLCγ2 (Hempel et al, 1992), mitogen-activated protein
(MAP) kinase (Casillas et al, 1991), GTPase activating protein (GAP) (Gold et al, 1992a) and phosphatidylinositol 3 -kinase (PI3-K) (Gold et al, 1992b). Recent studies have demonstrated an increase in tyrosine phosphorylation following irradiation of B-lymphocyte precursors (Uckun et al, 1993). Studies of p59f n, P56/p53lyn, p55bU and p56lck activity demonstrated that these Src-family tyrosine kinases were not responsible for radiation-induced tyrosine phosphorylation (Uckun et al, 1992a). These findings suggested that other protein tyrosine kinases, perhaps of the receptor-type, are involved in the response of cells to ionizing radiation.
SUMMARY OF THE INVENTION
It is, therefore, a goal of the present invention to exploit certain of the cell cycle pathways in order to circumvent aberrations in cellular growth regulation, thereby providing a method for the treatment of cancers. To this end, the inventors seek to exploit the p53-inducing properties of p300 and c-Abl.
Therefore, the present invention, in one embodiment, provides a method for increasing p53-mediated apoptosis in a tumor cell comprising the step of increasing the activity level of at least one of c-Abl and p300 in said tumor cell. The tumor cell may be derived from various tissues including brain, lung, liver, spleen, kidney, lymph node, small
intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue
In a preferred embodiment, the activity levels of both c-Abl and p300 are increased in said tumor cell Increasing activities may be accomplished (i) by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor cell in an amount effective to increase p53-mediated apoptosis, (ii) by providing at least one of a nucleic acid encoding c-Abl and a nucleic acid encoding p300 to said tumor cell, wherein said nucleic acid is operably linked to a promoter active in eukaryotic cells in an amount effective to increase p53-mediated apoptosis, or (iii) by providing an agent to said cell that increases the expression or stability of at least one of c-Abl and p300 in an amount effective to increase p53-mediated apoptosis
Delivery in of polypeptides via liposomes is specifically contemplated Delivery of nucleic acids, contained in viral expression vectors, via infection of target cells by encapsulated viral vectors also is contemplated Various viral vectors include herpesvirus, adenovirus, vaccinia virus, retrovirus and adeno-associated virus
Because p300 and c-Abl act though p53, it is important that the target cell express an active p53 molecule Thus, the method may further comprise determining the p53 activity of the target cell Where the target cell is defective in p53, and the method further comprises providing to said tumor cell a nucleic acid encoding a wild-type p53 operably linked to a promoter active in eukaryotic cells Again, the p53 nucleic acid preferably is contained in an expression vector, and more preferably in a viral vector
Combination therapies are advantageously employed with any of the foregoing embodiments For example, target cells may be subjected, either before or after the methods described above, to ionizing radiation or to a chemotherapeutic agent The ionizing radiation may be x-irradiation or γ-irradiation The chemotherapeutic agent may be mitomycin C, etoposide, genistin, cisplatin, 5-FU, adriamycin, doxorubicin, actinomycin D, verapamil, nitrosourea, ara-C and camptothecin
In another embodiment, there is provided a method for treating a patient having a tumor comprising the step of increasing the activity level of at least one of c-Abl and p300 in cells of said tumor Again, the activity level may be increased by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor in an amount effective to increase p53-mediated apoptosis in cells thereof, by providing at least one of a nucleic acid encoding c-Abl and a nucleic acid encoding p300 to said tumor, wherein said nucleic acid is operably linked to a promoter active in eukaryotic cells in an amount effective to increase p53-mediated apoptosis in cells thereof, or by providing an agent to said tumor that increases the expression or stability of at least one of c-Abl and p300 in an amount effective to increase p53-mediated apoptosis in cells thereof The polypeptide, nucleic acid or agent may be provided via intratumoral injection
Again, the p53 function of a cell is an important aspect of the invention Therefore, the method may further comprising screening the tumor cells to determine the p53 status thereof In addition, if the tumor cells lack p53 function, the method may further comprise providing to said tumor cells a nucleic acid encoding a wild-type p53 operably linked to a promoter active in eukaryotic cells The method may further take advantage of combined therapies, for example, by additionally treating the tumor with ionizing radiation or a chemotherapeutic agent
In still yet another embodiment, there is provided a method of screening a candidate substance for p53 -stimulatory activity comprising the steps of (i) providing a eukaryotic cell expressing a functional p300 polypeptide, (ii) contacting said cell with said candidate substance, and (iii) determining the effect of said candidate substance on the p300 level of said cell, wherein an increase in the p300 level in said cell, as compared to an untreated cell, indicates that said candidate substance increases p53 activity A similar method is provided where the effect of the candidate substance on c-Abl is determined
The p300 or c-Abl level may be measured by Western blot or ELISA Where the candidate substance is a nucleic acid encoding a polypeptide operably linked to a promoter active in eukaryotic cells, contacting comprises transferring said nucleic acid
into said cell Methods of transferring include transfection, lipofection, protoplast fusion, bombardment, electroporation or viral infection
In still yet other embodiments, there are provided (i) a use of at least one of a p300 and a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase p53-mediated apoptosis in a cell, (ii) a use of at least one of a nucleic acid encoding a p300 polypeptide and a nucleic acid encoding a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase apoptosis in a cell, (iii) a use of a p300 polypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer, and (iv) a use of a p300 polypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer
Still further embodiments of the present invention are kits for use in killing malignant cells or reducing their growth, as may be formulated into therapeutic kits for use in cancer treatment The kits of the invention will generally comprise, in suitable container means, pharmaceutical formulations of a p53 polypeptides or gene construct, c-Abl polypeptides or gene constructs and p300 polypeptides or gene constructs These agents may be present within a single container, or these components may be provided in distinct or separate container means Classical chemotherapeutic pharmaceutical preparations also are contemplated for use with the therapeutic compositions of the present invention
Other objects, features and advantages of the present invention will become apparent from the following detailed description It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein
FIGS. lA-C. Overexpression of kinase active c-Abl downregulates Cdk activity FIG 1A, MCF-7 cells were transfected with 2 μg p53-enhancer-luciferase plasmid (mdm2NA-Luc) and, (1) 8 μg control vector pSRaMSVtkNeo, (2) 5 and 8 μg c-abl vector, (3) 5 and 8 μg c-Aabl (K-R) vector, and (4) 5 and 8 μg c-ablΔPro4 vector Cells were also transfected with 2 μg SV40-promoter-luciferase plasmid (pGL2-control vector, Promega) and 8 μg c-Abl vector Luciferase activity was measured and normalized for protein concentration to that for control vector, D, MCF-7 cells were transfected with 8 μg control, c-abl, c-abl (K-R) of c-ablΔPro4 vector FIG IB, Cell lysates were immunoblotted with and-p21 (WAF1, Ab-1 Oncogene Solane) (top) and and-PCNA (PC 10 Santa Cruz Biotechnology) (bottom) FIG 1C, Cell lysates from the transient transfectants were imunoprecipitated (IP) with anti-Cdk2 (M2, Santa Cruz Biotechnology), followed by histone HI kinase assay (top) or immunoblotting (IB) with anti-Cdk2 (bottom)
FIGS. 2A-D. c-Abl kinase activity regulates irradiation (IR)-induced inhibition of Cdk2 FIG 2A, MCF-7 cells stably transfected with null pSR vector or c-abl (K-R) were treated with 5 Gy IR and collected after 3h Nuclei were isolated and nuclear proteins immunoprecipitated with anti-Abl (Ab-3, Oncogene Science) as described Immune- complex kinase was analyzed using a glutathione S transferase (GST)-Crk (120-225) fusion protein as substrate (top) And Abl immunoprecipitates were also analyzed by immunoblotting with anti-Abl (bottom) FIG 2B, Lysates were immunoblotted with anti- Abl, anti-p53 (Ab-6, Oncogene Science), anti-p21, anti-GADD45 (AT-26, Santa Cruz Biotechnology) and anti-c-Myc (9E10, Santa Cruz Biotechnology) FIG 2C, Lysates were immunoprecipitated with anti-Cdk2 Precipitates were analyzed by immunoblotting
with anti-p21 and anti-Cdk2 FIG 2D, Anti-Cdk2 immunoprecipitates were analyzed by histone HI kinase assay (top) or immunoblotting with anti-Cdk2 (bottom)
FIGS. 3A-D. c-Abl kinase activity regulates IR-induced growth arrest FIG 3 A, Representative two-dimensional FACS analysis of MCF-7/pSR and MCF-7/c-Abl (K-R) cells after exposure to 0 or 5 Gy IR Synchronized cells were irradiated and percentage of cells in S phase was assessed at 24h Boxes labeled Rl, R2 and R3 represent S, Gl and G2/M phase cells, respectively FIG 3B, Percentage of cells entering S phase after IR relative to control unirradiated cells Results are expressed as the mean ± s e of 6 experiments for each of two (a,b) independently selected clones FIG 3C, C57BL6 wild- type (ab h) and abl' MEFs were exposed to 0 or 5 Gy and collected at 3 h Cell lysates were immunoblotted with anti-Abl and anti-PCNA antibodies FIG 3D, abl+/+) and abl'' MEFs were exposed to 0 5 or 20 Gy IR Results (mean±s e of 5 experiments) are expressed as the percentage of cells entering S phase after IR relative to unirradiated cells
FIGS. 4A-D. c-Abl kinase downregulates Cdk2 activity by a p53-dependent. p21 -independent mechanism FIG 4A, Lysates were immunoprecipitated with anti-Abl (left) or anti-p53 (right) and the precipitates analyzed by immunoblotting with the indicated antibodies FIG 4B, MEFs (p597, p53+/+)n were transfected with the c-abl or c-abl (K-R) vectors and collected at 48 h FIG 4C, MEFs (abt' ab ')11 were exposed to D or 5 Gy and collected at the indicated times FIG 4D, MEFs (p2T , p21+/+ were transfected with the c-Abl or c-Abl (K-R) vectors and collected at 48 h Cell lysates were immunoprecipitated with anti-Cdk2 and the precipitates assayed for histone HI kinase activity (top) or immunoblotted with anti-Cdk2 (bottom) as described for FIGS 1 A-C
FIGS. 5. Effects of MMS on down-regulation of Cdk2 activity and growth arrest in Abl-deficient cells Percentage of cells in S phase at 9 h of MMS treatment relative to untreated cells Results are expressed as the mean = S E of six studies
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
Accumulation of wild-type p53 protein results in induction of two pathways, cell cycle arrest and programmed cell death or apoptosis A mutation in the p53 gene often inactivates these normal functions of the p53 gene and contribute to the malignant progression by gain of transforming potentiality As the understanding of p53 biology continues to grow, the promise grows of applying this knowledge to cancer therapy The introduction of wild-type p53 in a wide variety of p53 mutated cells using viral delivery- systems resulted in increased expression of wild-type p53 and suppressed the malignant phenotype which holds hope for the gene replacement strategy as a biological therapy
The sustained high level of wild-type p53 expression leads to cell death In other words, any means by which selective high level of p53 expression in the cancer cells is achieved could have potential implication in therapy of the disease
The c-Abl protein tyrosine kinase is activated by certain DNA-damaging agents, and its overexpression causes arrest in the Gl phase of the cell cycle by the tumor- suppressor protein p53 (Sawyers et al, 1994, Mattioni et al., 1995, Goga et al, 1995) The present investigators studied the role of c-Abl in growth arrest induced by DNA damage Transient transfection experiments using wild-type or inactivated c-Abl show that both induce expression of p21, an effector of p53, but only wild-type c-Abl down regulates the activity of the cyclin-dependent kinase Cdk2 and causes growth arrest
Exposure to ionizing radiation of cells that stably express active or inactive c-Abl is associated with induction of c-Abl/p53 complexes and p21 expression. However, cells expressing the dominant-negative c-Abl mutant and cells lacking the c-abl gene are impaired in their ability to down-regulate Cdk2 or undergo Gl arrest in response to ionizing radiation. It also is shown that expression of c-Abl kinase in p2r/_, but not in p53 _ ", cells results in down regulation of Cdk2 These results suggest that c-Abl kinase contributes to the regulation of growth arrest induced by ionizing radiation by a p53- dependent, p21 -independent mechanism
The present inventors also have demonstrated that c-Abl associates with p53 in the cellular response to the antimetabolite 1-β-D-arabinofuranosylcytosine (Ara-C) and the alkylating agent methyl methanesulfonate (MMS) Ara-C misincorporates into cellular DNA (Kufe et al, 1980, Major et al, 1981) and blocks replication by site-specific termination of DNA strands (Kufe et al, 1984, Ohno et al., 1988, Townsend and Cheng, 1987) MMS is a monofunctional alkylating agent that induces DNA base damage and strand breaks (Schwartz, 1986) The results indicate that the c-Abl kinase function is involved in the growth arrest response induced by these and certain other genotoxic agents
p300 is a nuclear protein originally identified for its ability to interact with adenovirus El A protein It is a regulator of transcription and interacts with a variety of cellular as well as viral proteins p300 possesses histone acetyltransferase activity resulting from either intrinsic activity and/or from an assocaited protein, P/CAF Bannister et al, 1996, Ogryzko et al, 1996, Yang et al, 1996 The acetylation of histones in thought to be involved in destabilization and restructuring of nucleosomes, which is likely a crucial event for accessibility of transcription factors to DNA templates These studies thus suggest that p300 participates in the transcription process by scaffolding different classes of transcriptional regulators on specific chromatin domains
A role for p300 in control of cellular growth has been proposed on the basis of the functional behavior of adenovirus El A and SV40 Tag proteins, which lose the ability to bind p300 Moran, 1993, Avantaggiati et al, 1996, Eckner et al, 1996a Such mutants are defective in the induction of cellular DNA synthesis and, in several instances, of transformation In addition, p300 is required for the activation of muscle-specific genes and for cell cycle arrest during differentiation of muscle cells. Eckner et al, 1996b, Puri et al, 1997. Moreover, mutations or translocation of the p300 gene has been described in human tumors. Borrow et al., 1996, Muraoka et al, 1996 p300 mutations in colorectal carcinomas are somatic and coupled to deletion of the second allele of the gene, suggesting that p300 is consequently inactivated It also is induced upon a cell's exposure
to radiation On the basis of this evidence, p300 is envisioned to be a negative regulator of cell growth
Because p300 and p53 both are implicated in regulation of transcription, the possibility has been raised that p53 and p300 interact in this endeavor It now has been demonstrated tha tp53 and p300 interact to form a specific protein complex in a variety of different cell types The binding of p300 to p53 apparently results in activation of p53- dependent promoters, inhibtion of AP-1 regulated enhancers, Gl arrest and apoptosis A fragment of p300 (p300 1514-1922) contains the regions required for interaction with p53 and can prevent p53 transcriptional activitation It also has been determined that p300 interacts with c-Abl c-Abl apparently phosphorylates p300 at one or more tyrosine residues, thereby activating p300 to interact with p53, thereby inducing the aforementioned p53-dependent actions
A fundamental role for p300 has been established in the activation of p53
Physical interaction of these two proteins has been documented p300 apparently is responsible for several p53-mediated functions, such as inhibition of API -regulated enhancers, transcriptional activation, apoptosis and cell cycle progression The present inventors have determined that p300 is activated by c-Abl More specifically, p300 is phosphorylated by a tyrosine kinase function of c-Abl This phosphorylation causes p300 interaction with p53, and the aforementioned activities
The related activities of these three molecules clearly impact on the ability of a cell, normal or abnormal, to progress through its cell cycle and proliferate These functions, along with normal cell senescence, represent key points at which malignant cells might be attacked in a therapeutic treatment
A. The Present Invention
The present invention exploits signaling pathways that are involved in the correction of DNA damage, in cell cycle progression and in apoptosis In particular, the methods involve the use of the c-Abl, p300 and p53 gene products to effect cellular responses to various external stimuli
In more particular aspects, the present invention provides a means of increasing the levels of wild-type p53 expression in tumor cells, thereby allowing for an increased apoptosis or reduction in cellular proliferation The inventors have discovered that c-Abl and p300 can increase the expression of wild-type p53 In using this discovery in cell therapy, cancers that express normal p53 can be treated with c-Abl genes or the c-Abl gene product, or with p300 or the corresponding p300 gene Secondly, the compositions of the present invention can be used to augment conventional gene therapy, where wild- type p53 is introduced into tumor cells concomitantly with c-Abl and/or p300 to increase the level of p53 so that programmed cell death is triggered A third way in which the present invention could be employed is in combination therapy, where gene therapy is used in combination with conventional chemotherapy and radiotherapy, and the c-Abl and p300 gene products are used to increase wild-type p53 expression thereby inducing programmed cell death
Therefore, the present application is drawn, in one embodiment, to methods of screening cells for their ability to express wild-type p53 protein expression of cancer cells and to concomitantly induce apoptosis in said cells To augment the expression of p53, one would then add the c-Abl gene product and/or p300 to a cell If wild-type p53 is lacking in a cell, wild-type p53 and c-Abl are administered to a cell in combination to induce the apoptotic response
"Effective amounts" are those amounts of compositions effective at reproducibly increasing wild-type p53 expression in cancer cells in comparison to their normal levels Compounds that achieve significant appropriate changes in activity will be used A significant increase in wild-type p53 expression, e.g., as measured using for example,
Western blot analysis, are represented by an increase in wild-type p53 levels of at least about 30%-40%, and most preferably, by increases of at least about 50%, with higher values of course being possible Assays that measure p53 content and expression in cells are well known in the art and may be conducted in vitro or in vivo
Alternatively, it may be desirable simply to measure inhibition of growth of cancer cells, for example, by measuring growth according to the MTT assay A significant
inhibition in growth is represented by decreases of at least about 30%-40% as compared to uninhibited, and most preferably, of at least about 50%, with more significant decreases also being possible. Growth assays as measured by the MTT assay are well known in the art Assays may be conducted as described by Mosmann et al, 1983; Rubinstein et al, 1990 (incorporated herein by reference) Therefore, if a candidate substance exhibited inhibition of growth of cancer cells in this type of study, it would likely be a suitable compound for use in the present invention.
The more preferred approach will involve the preparation of vectors that incorporate nucleic acid sequences that encode the c-Abl and p300 sequences It is contemplated that these vectors may either be transiently incorporated into the host cell, or may be stably integrated into the host cell genome This expression preferably occurs in a mammalian cell, and even more preferably, the mammalian cell is a human cell. Examples of suitable vectors for use within the scope of the present invention include, but are not limited to, adenovirus, adeno-associated virus, retrovirus or herpes simplex virus 1.
Therefore, in certain aspects, the present invention contemplates the preparation of nucleic acid molecules that comprise a coding region that contains regions complementary to and capable of hybridizing with a c-Abl gene sequence. Generally, the preferred nucleic acid molecules will be DNA sequences arranged in a vector, such as a virus or plasmid, and positioned under the control of an appropriate promoter. However, as previously set forth, the antisense RNA molecule may itself be an appropriate nucleic acid, such as retrovirus RNA into which the appropriate coding sequences have been incorporated. Moreover, the nucleic acids may be introduced into cells by means of liposomes, or the like.
To kill malignant cells or reduce their growth, using the methods and compositions of the present invention, one would generally contact a "target" cell with a c-Abl and/or p300 construct in a combined amount effective to kill the cell. This process may involve contacting the cells with the p53 construct and c-Abl/p300 construct(s) at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes the p53 construct and the other
composition includes the c-Abl construct Naturally, it is also envisioned that the target cell, where lacking a functional p53 molecule, may be first exposed to a p53 expression construct and then contacted with a c-Abl or p300 construct, or vice versa
The terms "contacted" and "exposed", when applied to a cell, are used herein to describe the process by which a p53 or c-Abl construct are delivered to a target cell or are placed in direct juxtaposition with the target cell To achieve cell killing or reduced cell growth, either one or both agents are delivered to a cell in a combined amount effective to kill the cell, i.e , to induce programmed cell death or apoptosis The terms, "killing," "programmed cell death" and "apoptosis" are used interchangeably in the present text to describe a series of intracellular events that lead to target cell death Reduced cell growth refers to a lower rate of cellular proliferation than observed for the untreated cells
The specific embodiments of the present invention, as set out above, are explained in greater detail as follows
B. p53 As a Tumor Suppressor p53 is currently recognized as a tumor suppressor gene (Montenarh, 1992) High levels have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40 The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992) It is mutated in over 50% of human NSCLC (Hollestein et al, 1991) and in a wide spectrum of other tumors
The p53 gene encodes a 393-amino-acid phosphoprotein that can form complexes with host proteins such as large-T antigen and E1B The protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue Interestingly, wild-type p53 appears to be important in regulating cell growth and division Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines Thus p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell
growth or indirectly activate genes that suppress this growth Thus, absence or inactivation of wild type p53 may contribute to transformation However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene
Wild-type p53 is recognized as an important growth regulator in many cell types Mis-sense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene A single genetic change prompted by point mutations can create carcinogenic p53 Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991)
Casey and colleagues have reported that transfection of DNA encoding wild-type p53 into two human breast cancer cell lines restores growth suppression control in such cells (Casey et al, 1991) A similar effect has also been demonstrated on transfection of wild-type, but not mutant, p53 into human lung cancer cell lines (Takahasi et al, 1992) The p53 appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene Normal expression of the transfected p53 does not affect the growth of cells with endogenous p53 Thus, such constructs might be taken up by normal cells without adverse effects
It is thus possible that the treatment of p53 -associated cancers with wild type p53 may reduce the number of malignant cells However, studies such as those described above are far from achieving such a goal, not least because DNA transfection cannot be employed to introduce DNA into cancer cells within a patients' body
C. Treatment of p53 Positive Cancers Using c-Abl and p300
A patient presenting a p53-positive tumor that expresses wild-type p53 will be treated with c-Abl and/or p300 based therapies In such a case, the p53 status of the tumor cells will be determined using any conventional methods, examples of which are described below Patients may, but need not, have received previous chemo-, radio- or gene therapies Optimally, patients will have adequate bone marrow function (defined as peripheral absolute granulocyte count of > 2,000/mm3 and platelet count of 100,000/mm3), adequate liver function (bilirubin < 1 5 mg/dl) and adequate renal function (creatinine < 1 5 mg/dl)
The patient will be treated with a pharmaceutically acceptable form of the c-Abl and/or p300 gene products, or will be treated by gene therapy techniques that will allow the in vivo expression of the c-Abl or p300 gene products Alternatively, the patient may be treated with a substance that augments the expressionon c-Abl or p300 normally produced by the target cell Treatment regimens normally last between about 3 and 6 weeks, and involve repeat dosings In order to know whether a cell will respond to provision of c-Abl and/or p300, it must first be determined whether the cell expresses an active p53 molecule Thus, screening for p53 expression is an important first step
1 Determination of p53 Status of Target Cells
A wide variety of detection methods can be employed in the present invention to detect the p53 status of a cell There are numerous antibodies to the p53 protein, hence any assay that utilizes antibodies for detection, for example, ELISAs, Western Blotting, immunoassay techniques etc Alternatively, assays that employ nucleotide probes may be used to identify the presence/absence/status of p53, for example, Southern blotting,
Northern blotting or PCR techniques All the above techniques are well known to one of skill in the art and could be utilized in the present invention without undue experimentation.
i ELISAs, Immunoassay and Immunohistological Assay
Immunoassays encompassed by the present invention include, but are not limited to those described in U S Patent No 4,367,110 (double monoclonal antibody sandwich
assay) and U S Patent No 4,452,901 (Western blot) Other assays include immunoprecipitation of labeled ligands and immunocytochemistry, both in vitro and in vivo
Immunoassays, in their most simple and direct sense, are binding assays Certain preferred immunoassays are the various types of enzyme linked immunosorbent assays (ELISAs) and radioimmunoassays (RIA) known in the art Immunohistochemical detection using tissue sections is also particularly useful
In one exemplary ELISA, anti-p53 antibodies are immobilized onto a selected surface exhibiting protein affinity, such as a well in a polystyrene microtiter plate Then, a test composition suspected of containing the desired antigen, such as a clinical sample, is added to the wells After binding and washing to remove non-specifically bound immune complexes, the bound antigen may be detected Detection is generally achieved by the addition of another antibody, specific for the desired antigen, that is linked to a detectable label This type of ELISA is a simple "sandwich ELISA" Detection may also be achieved by the addition of a second antibody specific for the desired antigen, followed by the addition of a third antibody that has binding affinity for the second antibody, with the third antibody being linked to a detectable label
Varaitions of ELISA techniques are know to those of skill in the art In one such variation, the samples suspected of containing the desired antigen are immobilized onto the well surface and then contacted with the antibodies of the invention After binding and appropriate washing, the bound immune complexes are detected Where the initial antigen specific antibodies are linked to a detectable label, the immune complexes may be detected directly Again, the immune complexes may be detected using a second antibody that has binding affinity for the first antigen specific antibody, with the second antibody being linked to a detectable label
Competition ELISAs are also possible in which test samples compete for binding with known amounts of labeled antigens or antibodies The amount of reactive species in the unknown sample is determined by mixing the sample with the known labeled species
before or during incubation^ with coated wells The presence of reactive species in the sample acts to reduce the amount of labeled species available for binding to the well and thus reduces the ultimate signal
Irrespective of the format employed, ELISAs have certain features in common, such as coating, incubating or binding, washing to remove non-specifically bound species, and detecting the bound immune complexes These are described as below
Antigen or antibodies may also be linked to a solid support, such as in the form of plate, beads, dipstick, membrane or column matrix, and the sample to be analyzed applied to the immobilized antigen or antibody In coating a plate with either antigen or antibody, one will generally incubate the wells of the plate with a solution of the antigen or antibody, either overnight or for a specified period The wells of the plate will then be washed to remove incompletely adsorbed material Any remaining available surfaces of the wells are then "coated" with a nonspecific protein that is antigenically neutral with regard to the test antisera These include bovine serum albumin (BSA), casein and solutions of milk powder The coating allows for blocking of nonspecific adsorption sites on the immobilizing surface and thus reduces the background caused by nonspecific binding of antisera onto the surface
In ELISAs, it is probably more customary to use a secondary or tertiary detection means rather than a direct procedure Thus, after binding of the antigen or antibody to the well, coating with a non-reactive material to reduce background, and washing to remove unbound material, the immobilizing surface is contacted with the clinical or biological sample to be tested under conditions effective to allow immune complex
(antigen/antibody) formation Detection of the immune complex then requires a labeled secondary binding ligand or antibody, or a secondary binding ligand or antibody in conjunction with a labeled tertiary antibody or third binding ligand
"Under conditions effective to allow immune complex (antigen/antibody) formation" means that the conditions preferably include diluting the antigens and antibodies with solutions such as BSA, bovine gamma globulin (BGG) and phosphate
buffered saline (PBS)/Tween These added agents also tend to assist in the reduction of nonspecific background
The suitable conditions also mean that the incubation is at a temperature and for a period of time sufficient to allow effective binding Incubation steps are typically from about 1 to 2 to 4 hours, at temperatures preferably on the order of 25° to 27°C, or may be overnight at about 4°C or so
Following all incubation steps in an ELISA, the contacted surface is washed so as to remove non-complexed material Washing often includes washing with a solution of
PBS/Tween, or borate buffer Following the formation of specific immune complexes between the test sample and the originally bound material, and subsequent washing, the occurrence of even minute amounts of immune complexes may be determined.
To provide a detecting means, the second or third antibody will have an associated label to allow detection Preferably, this will be an enzyme that will generate color development upon incubating with an appropriate chromogenic substrate Thus, for example, one will desire to contact and incubate the first or second immune complex with a urease, glucose oxidase, alkaline phosphatase or hydrogen peroxidase-conjugated antibody for a period of time and under conditions that favor the development of further immune complex formation, e.g., incubation for 2 hours at room temperature in a PBS-containing solution such as PBS-Tween.
After incubation with the labeled antibody, and subsequent to washing to remove unbound material, the amount of label is quantified, e.g., by incubation with a chromogenic substrate such as urea and bromocresol purple or 2,2'-azino-di-(3-ethyl-benzthiazoline-6-sulfonic acid [ABTS] and H2O , in the case of peroxidase as the enzyme label. Quantification is then achieved by measuring the degree of color generation, e.g., using a visible spectra spectrophotometer
Alternatively, the label may be a chemiluminescent one. The use of such labels is described in U.S. Patent Nos. 5,310,687, 5,238,808 and 5,221,605.
Assays for the p53„ status of the cell can determine normal/abnormal tissue distribution for diagnostic purposes Methods for in vitro and in situ analysis are well known and involve assessing binding of antigen-specific antibodies to tissues, cells or cell extracts These are conventional techniques well within the grasp of those skilled in the art For example, the antibodies to p53 may be used in conjunction with both fresh-frozen and formalin-fixed, paraffin-embedded tissue blocks prepared for study by immunohistochemistry (IHC) Each tissue block may consist of 50 mg of residual "pulverized" tumor The method of preparing tissue blocks from these particulate specimens has been successfully used in previous IHC studies of various prognostic factors, e.g., in breast cancer, and is well known to those of skill in the art (Abbondanzo et al, 1990, Alfred et al, 1990, Brown et al, 1990)
Briefly, frozen-sections may be prepared by rehydrating 50 ng of frozen pulverized tumor at room temperature in PBS in small plastic capsules, pelleting the particles by centrifugation, resuspending them in a viscous embedding medium (OCT), inverting the capsule and pelleting again by centrifugation, snap-freezing in -70°C isopentane, cutting the plastic capsule and removing the frozen cylinder of tissue, securing the tissue cylinder on a cryostat microtome chuck, and cutting 25-50 serial sections containing an average of about 500 remarkably intact tumor cells
Permanent-sections may be prepared by a similar method involving rehydration of the 50 mg sample in a plastic microfuge tube, pelleting, resuspending in 10% formalin for 4 hours fixation, washing/pelleting; resuspending in warm 2 5% agar, pelleting, cooling in ice water to harden the agar; removing the tissue/agar block from the tube, infiltrating and embedding the block in paraffin, and cutting up to 50 serial permanent sections
ii Detection of p53 Nucleic Acids
In some situations, it may be preferable to look for p53 nucleic acids, in particular, for DNA's, cDNA's and mRNA's encoding p53 Nucleic acids may be isolated from cells according to standard methodologies (Sambrook et al, 1989) The nucleic acid may be genomic DNA or fractionated or whole cell RNA Where mRNA is used, it may be
desired to convert the mRNA to a complementary DNA In one embodiment, the RNA is whole cell RNA, in another, it is poly-A RNA Normally, the nucleic acid is amplified
Depending on the format, the specific nucleic acid of interest is identified in the sample directly using amplification or with a second, known nucleic acid following amplification Next, the identified product is detected In certain applications, the detection may be performed by visual means (e.g., ethidium bromide staining of a gel) Alternatively, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of radiolabel or fluorescent label or even via a system using electrical or thermal impulse signals
Various types of defects are to be identified Thus, "alterations" should be read as including deletions, insertions, point mutations and duplications Point mutations result in stop codons, frameshift mutations or amino acid substitutions Somatic mutations are those occurring in non-germline tissues Germ-line tissue can occur in any tissue and are inherited Mutations in and outside the coding region also may affect the amount of p53 produced, both by altering the transcription of the gene or in destabilizing or otherwise altering the processing of either the transcript (mRNA) or protein
A variety of different assays are contemplated in this regard, including but not limited to, fluorescent in situ hybridization (FISH), direct DNA sequencing, PFGE analysis, Southern or Northern blotting, single-stranded conformation analysis (SSCA), RNAse protection assay, allele-specific oligonucleotide (ASO), dot blot analysis, denaturing gradient gel electrophoresis, RFLP and PCR-SSCP
The term primer, as defined herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process Typically, primers are oligonucleotides from ten to twenty base pairs in length, but longer sequences can be employed Primers may be provided in double-stranded or single-stranded form, although the single-stranded form is preferred Probes are defined differently, although they may act as primers Probes, while perhaps capable of priming,
are designed to binding to the target DNA or RNA and need not be used in an amplification process
In preferred embodiments, the probes or primers are labeled with radioactive species (32P, 14C, 35S, 3H, or other label), with a fluorophore (rhodamine, fluorescein) or a chemillumiscent (luciferase)
A number of template dependent processes are available to amplify the marker sequences present in a given template sample One of the best known amplification methods is the polymerase chain reaction (referred to as PCR™) which is described in detail in U S Patent Nos 4,683,195, 4,683,202 and 4,800, 159, each of which is incorporated herein by reference in its entirety
Briefly, in PCR, two primer sequences are prepared that are complementary to regions on opposite complementary strands of the marker sequence An excess of deoxynucleoside triphosphates are added to a reaction mixture along with a DNA polymerase, e.g. , Taq polymerase If the marker sequence is present in a sample, the primers will bind to the marker and the polymerase will cause the primers to be extended along the marker sequence by adding on nucleotides By raising and lowering the temperature of the reaction mixture, the extended primers will dissociate from the marker to form reaction products, excess primers will bind to the marker and to the reaction products and the process is repeated
A reverse transcriptase PCR amplification procedure may be performed in order to quantify the amount of mRNA amplified Methods of reverse transcribing RNA into cDNA are well known and described in Sambrook et al, 1989 Alternative methods for reverse transcription utilize thermostable, RNA-dependent DNA polymerases These methods are described in WO 90/07641 filed December 21, 1990 Polymerase chain reaction methodologies are well known in the art
Another method for amplification is the ligase chain reaction ("LCR"), disclosed in EPO No 320 308, incorporated herein by reference in its entirety In LCR, two
complementary probe pairs are prepared, and in the presence of the target sequence, each pair will bind to opposite complementary strands of the target such that they abut In the presence of a ligase, the two probe pairs will link to form a single unit By temperature cycling, as in PCR, bound ligated units dissociate from the target and then serve as "target sequences" for ligation of excess probe pairs U S Patent 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence
Qbeta Replicase, described in PCT Application No PCT US87/00880, may also be used as still another amplification method in the present invention In this method, a replicative sequence of RNA that has a region complementary to that of a target is added to a sample in the presence of an RNA polymerase The polymerase will copy the replicative sequence that can then be detected
An isothermal amplification method, in which restriction endonucleases and ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha- thio]-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention, Walker et al, (1992)
Strand Displacement Amplification (SDA) is another method of carrying out isothermal amplification of nucleic acids which involves multiple rounds of strand displacement and synthesis, i.e., nick translation A similar method, called Repair Chain
Reaction (RCR), involves annealing several probes throughout a region targeted for amplification, followed by a repair reaction in which only two of the four bases are present The other two bases can be added as biotinylated derivatives for easy detection A similar approach is used in SDA Target specific sequences can also be detected using a cyclic probe reaction (CPR) In CPR, a probe having 3' and 5' sequences of non-specific
DNA and a middle sequence of specific RNA is hybridized to DNA that is present in a sample Upon hybridization, the reaction is treated with RNase H, and the products of the probe identified as distinctive products that are released after digestion The original template is annealed to another cycling probe and the reaction is repeated
Still another amplification methods described in GB Application No 2 202 328, and in PCT Application No PCT/US89/01025, each of which is incorporated herein by reference in its entirety, may be used in accordance with the present invention In the former application, "modified" primers are used in a PCR-like, template- and enzyme- dependent synthesis The primers may be modified by labeling with a capture moiety
(e.g., biotin) and/or a detector moiety (e.g., enzyme) In the latter application, an excess of labeled probes are added to a sample In the presence of the target sequence, the probe binds and is cleaved catalytically After cleavage, the target sequence is released intact to be bound by excess probe Cleavage of the labeled probe signals the presence of the target sequence
Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Kwoh et al, 1989, Gingeras et al, PCT Application WO 88/10315, incorporated herein by reference in their entirety) In NASBA, the nucleic acids can be prepared for amplification by standard phenol/chloroform extraction, heat denaturation of a clinical sample, treatment with lysis buffer and minispin columns for isolation of DNA and RNA or guanidinium chloride extraction of RNA These amplification techniques involve annealing a primer which has target specific sequences Following polymerization, DNA/RNA hybrids are digested with RNase H while double stranded
DNA molecules are heat denatured again In either case the single stranded DNA is made fully double stranded by addition of second target specific primer, followed by polymerization The double-stranded DNA molecules are then multiply transcribed by an RNA polymerase such as T7 or SP6 In an isothermal cyclic reaction, the RNA's are reverse transcribed into single stranded DNA, which is then converted to double stranded
DNA, and then transcribed once again with an RNA polymerase such as T7 or SP6 The resulting products, whether truncated or complete, indicate target specific sequences
Davey et al, EPO No 329 822 (incorporated herein by reference in its entirety) disclose a nucleic acid amplification process involving cyclically synthesizing single- stranded RNA ("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention The ssRNA is a template for a first primer
oligonucleotide, which is elongated by reverse transcriptase (RNA-dependent DNA polymerase) The RNA is then removed from the resulting DNA RNA duplex by the action of ribonuclease H (RNase H, an RNase specific for RNA in duplex with either DNA or RNA) The resultant ssDNA is a template for a second primer, which also includes the sequences of an RNA polymerase promoter (exemplified by T7 RNA polymerase) 5' to its homology to the template This primer is then extended by DNA polymerase (exemplified by the large "Klenow" fragment of E. coli DNA polymerase I), resulting in a double-stranded DNA ("dsDNA") molecule, having a sequence identical to that of the original RNA between the primers and having additionally, at one end, a promoter sequence This promoter sequence can be used by the appropriate RNA polymerase to make many RNA copies of the DNA These copies can then re-enter the cycle leading to very swift amplification With proper choice of enzymes, this amplification can be done isothermally without addition of enzymes at each cycle Because of the cyclical nature of this process, the starting sequence can be chosen to be in the form of either DNA or RNA
Miller et al. , PCT Application WO 89/06700 (incorporated herein by reference in its entirety) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence This scheme is not cyclic, i.e., new templates are not produced from the resultant RNA transcripts Other amplification methods include "RACE" and "one-sided PCR" (Frohman, M A , In PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS, Academic Press, N Y , 1990, herein incorporated by reference in its entirety)
Methods based on ligation of two (or more) oligonucleotides in the presence of nucleic acid having the sequence of the resulting "di-oligonucleotide", thereby amplifying the di-oligonucleotide, may also be used in the amplification step of the present invention Wu et al, (1989), incorporated herein by reference in its entirety
Blotting techniques are well known to those of skill in the art Southern blotting involves the use of DNA as a target, whereas Northern blotting involves the use of RNA
as a target Each provide different types of information, although cDNA blotting is analogous, in many aspects, to blotting or RNA species
Briefly, a probe is used to target a DNA or RNA species that has been immobilized on a suitable matrix, often a filter of nitrocellulose The different species should be spatially separated to facilitate analysis This often is accomplished by gel electrophoresis of nucleic acid species followed by "blotting" on to the filter
Subsequently, the blotted target is incubated with a probe (usually labeled) under conditions that promote denaturation and rehybridization Because the probe is designed to base pair with the target, the probe will binding a portion of the target sequence under renaturing conditions Unbound probe is then removed, and detection is accomplished as described above
It normally is desirable, at one stage or another, to separate the amplification product from the template and the excess primer for the purpose of determining whether specific amplification has occurred In one embodiment, amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods See Sambrook et al, 1989
Alternatively, chromatographic techniques may be employed to effect separation There are many kinds of chromatography which may be used in the present invention adsorption, partition, ion-exchange and molecular sieve, and many specialized techniques for using them including column, paper, thin-layer and gas chromatography
Products may be visualized in order to confirm amplification of the marker sequences One typical visualization method involves staining of a gel with ethidium bromide and visualization under UV light Alternatively, if the amplification products are integrally labeled with radio- or fluorometrically-labeled nucleotides, the amplification products can then be exposed to x-ray film or visualized under the appropriate stimulating spectra, following separation
In one embodiment^ visualization is achieved indirectly Following separation of amplification products, a labeled nucleic acid probe is brought into contact with the amplified marker sequence The probe preferably is conjugated to a chromophore but may be radiolabeled In another embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, and the other member of the binding pair carries a detectable moiety
In one embodiment, detection is by a labeled probe The techniques involved are well known to those of skill in the art and can be found in many standard books on molecular protocols See Sambrook et al, 1989 For example, chromophore or radiolabel probes or primers identify the target during or following amplification
One example of the foregoing is described in U S Patent No 5,279,721, incorporated by reference herein, which discloses an apparatus and method for the automated electrophoresis and transfer of nucleic acids The apparatus permits electrophoresis and blotting without external manipulation of the gel and is ideally suited to carrying out methods according to the present invention
In addition, the amplification products described above may be subjected to sequence analysis to identify specific kinds of variations using standard sequence analysis techniques Within certain methods, exhaustive analysis of genes is carried out by sequence analysis using primer sets designed for optimal sequencing (Pignon et al, 1994) The present invention provides methods by which any or all of these types of analyses may be used Using the sequences disclosed herein, oligonucleotide primers may be designed to permit the amplification of sequences throughout the p53 gene that may then be analyzed by direct sequencing
All the essential materials and reagents required for detecting and sequencing p53 and variants thereof may be assembled together in a kit This generally will comprise preselected primers and probes Also included may be enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, Sequenase™, etc ), deoxynucleotides and buffers to provide the necessary reaction mixture for amplification
Such kits also generally will comprise, in suitable means, distinct containers for each individual reagent and enzyme as well as for each primer or probe
Specifically contemplated by the present inventors are chip-based DNA technologies such as those described by Hacia et al. (1996) and Shoemaker et al. (1996)
Briefly, these techniques involve quantitative methods for analyzing large numbers of genes rapidly and accurately By tagging genes with oligonucleotides or using fixed probe arrays, one can employ chip technology to segregate target molecules as high density arrays and screen these molecules on the basis of hybridization See also Pease et al. (1994), Fodor et α/. (1991)
2 Treatment Protocol
Patients exhibiting neoplastic, p53-positive disease are treated with a c-Abl and optionally or alternatively, p300 polypeptide or a gene construct that comprises a c-Abl sequence, and optionally or alternatively, a p300 sequence These genetic constructs are used in combination with a recombinant vector that comprises a nucleic acid sequence capable of expressing the desired gene sequence in the cell The vector typically is introduced into the cell in a manner that allows expression of the encoded gene sequence at a level sufficient to effect cell function and cause an apoptotic response or to reduce cell proliferation The following is a discussion of genetic constructs and gene transfer methods
i Expression Vectors
Throughout this application, the term "expression construct" is meant to include any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed The transcript may be translated into a protein, but it need not be Thus, in certain embodiments, expression includes both transcription of a p53, p300 or c-Abl gene and translation of p53, p300 or c-Abl mRNA into the proper protein product
In order for the construct to effect expression of a p53, p300 or c-Abl transcript, the polynucleotide encoding p53, p300 or c-Abl will be under the transcriptional control of a promoter A "promoter" refers to a DNA sequence recognized by the synthetic
machinery of the host cell, or introduced synthetic machinery, that is required to initiate the specific transcription of a gene The phrase "under transcriptional control" means that the promoter is in the correct location in relation to the polynucleotide to control RNA polymerase initiation and expression of the polynucleotide
The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator or repressor proteins
At least one module in each promoter functions to position the start site for RNA synthesis The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation
Additional promoter elements regulate the frequency of transcriptional initiation Typically, these are located in the region 30-1 10 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well The spacing between promoter elements frequently is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another In the tk promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline Depending on the promoter, it appears that individual elements can function either cooperatively or independently to activate transcription
The particular promoter that is employed to control the expression of ap53 or c- Abl polynucleotide is not believed to be critical, so long as it is capable of expressing the
polynucleotide in the targeted cell Thus, where a human cell is targeted, it is preferable to position the polynucleotide coding region adjacent to and under the control of a promoter that is capable of being expressed in a human cell Generally speaking, such a promoter might include either a human or viral promoter
In various embodiments, the human cytomegalovirus (CMV) immediate early gene promoter, the SV40 early promoter and the Rous sarcoma virus long terminal repeat can be used to obtain high-level expression of the p53 or c-Abl polynucleotide The use of other viral or mammalian cellular or bacterial phage promoters which are well-known in the art to achieve expression of polynucleotides is contemplated as well, provided that the levels of expression are sufficient to produce a growth inhibitory effect
By employing a promoter with well-known properties, the level and pattern of expression of a polynucleotide following transfection can be optimized For example, selection of a promoter which is active in specific cells, such as tyrosinase (melanoma), alpha-fetoprotein and albumin (liver tumors), CC10 (lung tumor) and prostate-specific antigen (prostate tumor) will permit tissue-specific expression of p53 or c-Abl constructs Table 1 lists several elements/promoters which may be employed, in the context of the present invention, to regulate the expression oϊp53 or c-Abl constructs This list is not intended to be exhaustive of all the possible elements involved in the promotion of p53 or c-Abl expression but, merely, to be exemplary thereof
Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins
The basic distinction between enhancers and promoters is operational An enhancer region as a whole must be able to stimulate transcription at a distance, this need not be true of a promoter region or its component elements On the other hand, a
promoter must have one or. more elements that direct initiation of RNA synthesis at a particular site and in a particular orientation, whereas enhancers lack these specificities Promoters and enhancers are often overlapping and contiguous, often seeming to have a very similar modular organization
Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of a p53, p300 or c-Abl construct Use of a T3, T7 or SP6 cytoplasmic expression system is another possible embodiment Eukaryotic cells can support cytoplasmic transcription from certain bacteriophage promoters if the appropriate bacteriophage polymerase is provided, either as part of the delivery complex or as an additional genetic expression vector
TABLE 1
ENHANCER
Immunoglobulin Heavy Chain
Immunoglobulin Light Chain
T-Cell Receptor
HLA DQ α and DQ β β-Interferon
Interleukin-2
Interleukin-2 Receptor
MHC Class II 5
MHC Class II HLA-DRα β-Actin
Muscle Creatine Kinase
Prealbumin (Transthyretin)
Elastase /
Metallothionein
Collagenase
Albumin Gene α-Fetoprotein τ-Globin β-Globin c-fos c-HA-ras
Insulin
Neural Cell Adhesion Molecule (NCAM) cti-Antitrypsin
H2B (TH2B) Histone
Mouse or Type I Collagen
Glucose-Regulated Proteins (GRP94 and GRP78)
ENHANCER
Rat Growth Hormone
Human Serum Amyloid A (SAA)
Troponin I (TN I)
Platelet-Derived Growth Factor
Duchenne Muscular Dystrophy
SV40
Polyoma
Retro viruses
Papilloma Virus
Hepatitis B Virus
Human Immunodeficiency Virus
Cytomegalovirus
Gibbon Ape Leukemia Virus
Further, selection of a promoter that is regulated in response to specific physiologic signals can permit inducible expression of the p53 construct. For example, with the polynucleotide under the control of the human PAI-1 promoter, expression is inducible by tumor necrosis factor. Table 2 illustrates several promoter/inducer combinations:
TABLE 2
In certain embodiments of the invention, the delivery of an expression vector in a cell may be identified in vitro or in vivo by including a marker in the expression vector The marker would result in an identifiable change to the transfected cell permitting easy identification of expression Usually the inclusion of a drug selection marker aids in cloning and in the selection of transformants Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) (eukaryotic) or chloramphenicol acetyltransferase (CAT) (prokaryotic) may be employed Immunologic markers also can be employed
The selectable marker employed is not believed to be important, so long as it is capable of being expressed along with the polynucleotide encoding p53 Further examples of selectable markers are well known to one of skill in the art
One will typically include a polyadenylation signal to effect proper polyadenylation of the transcript The nature of the polyadenylation signal is not believed to be crucial to the successful practice of the invention, and any such sequence may be employed The inventor has employed the SV40 polyadenylation signal in that it was convenient and known to function well in the target cells employed Also contemplated as an element of the expression construct is a terminator These elements can serve to enhance message levels and to minimize read through from the construct into other sequences
In certain embodiments of the invention, the cells contain nucleic acid constructs of the present invention, a cell may be identified in vitro or in vivo by including a marker in the expression construct Such markers would confer an identifiable change to the cell permitting easy identification of cells containing the expression construct Usually the inclusion of a drug selection marker aids in cloning and in the selection of transformants, for example, genes that confer resistance to neomycin, puromycin, hygromycin, DHFR, GPT, zeocin and histidinol are useful selectable markers Alternatively, enzymes such as herpes simplex virus thymidine kinase (tk) or chloramphenicol acetyltransferase (CAT) may be employed Immunologic markers also can be employed The selectable marker employed is not believed to be important, so long as it is capable of being expressed simultaneously with the nucleic acid encoding a gene product Further examples of selectable markers are well known to one of skill in the art
In certain embodiments of the invention, the use of internal ribosome binding sites (IRES) elements are used to create multigene, or polycistronic, messages IRES elements are able to bypass the ribosome scanning model of 5' methylated Cap dependent translation and begin translation at internal sites (Pelletier and Sonenberg, 1988) IRES elements from two members of the picanovirus family (polio and encephalomyocarditis) have been described (Pelletier and Sonenberg, 1988), as well an IRES from a mammalian
message (Macejak and Sarnow, 1991) IRES elements can be linked to heterologous open reading frames Multiple open reading frames can be transcribed together, each separated by an IRES, creating polycistronic messages By virtue of the IRES element, each open reading frame is accessible to ribosomes for efficient translation Multiple genes can be efficiently expressed using a single promoter/enhancer to transcribe a single message
Any heterologous open reading frame can be linked to IRES elements This includes genes for secreted proteins, multi-subunit proteins, encoded by independent genes, intracellular or membrane-bound proteins and selectable markers In this way, expression of several proteins can be simultaneously engineered into a cell with a single construct and a single selectable marker
In preferred embodiments of the present invention, the expression construct comprises a virus or engineered construct derived from a viral genome The ability of certain viruses to enter cells via receptor-mediated endocytosis and, in some cases, integrate into the host cell chromosomes, have made them attractive candidates for gene transfer in to mammalian cells However, because it has been demonstrated that direct uptake of naked DNA, as well as receptor-mediated uptake of DNA complexes (discussed below), expression vectors need not be viral but, instead, may be any plasmid, cosmid or phage construct that is capable of supporting expression of encoded genes in mammalian cells, such as pUC or Bluescript™ plasmid series
The retroviruses are a group of single-stranded RNA viruses characterized by an ability to convert their RNA to double-stranded DNA in infected cells by a process of reverse-transcription (Coffin, 1990) The resulting DNA then stably integrates into cellular chromosomes as a provirus and directs synthesis of viral proteins The integration results in the retention of the viral gene sequences in the recipient cell and its descendants The retroviral genome contains three genes - gag, pol, and env - that code for capsid proteins, polymerase enzyme, and envelope components, respectively A sequence found upstream from the gag gene, termed Ψ, functions as a signal for packaging of the genome
into virions Two long terminal repeat (LTR) sequences are present at the 5' and 3' ends of the viral genome These contain strong promoter and enhancer sequences and are also required for integration in the host cell genome (Coffin, 1990)
In order to construct a retroviral vector, a nucleic acid encoding a p53 is inserted into the viral genome in the place of certain viral sequences to produce a virus that is replication-defective In order to produce virions, a packaging cell line containing the gag, pol and env genes but without the LTR and Ψ components is constructed (Mann et al, 1983) When a recombinant plasmid containing a human cDNA, together with the retroviral LTR and Ψ sequences is introduced into this cell line (by calcium phosphate precipitation for example), the Ψ sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then secreted into the culture media (Nicolas and Rubenstein, 1988, Temin, 1986, Mann et al, 1983) The media containing the recombinant retroviruses is then collected, optionally concentrated, and used for gene transfer Retroviral vectors are able to infect a broad variety of cell types However, integration and stable expression require the division of host cells (Paskind et al, 1975)
A novel approach designed to allow specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the chemical addition of lactose residues to the viral envelope This modification could permit the specific infection of hepatocytes via sialoglycoprotein receptors
A different approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies against a retroviral envelope protein and against a specific cell receptor were used The antibodies were coupled via the biotin components by using streptavidin (Roux et al, 1989) Using antibodies against major histocompatibility complex class I and class II antigens, they demonstrated the infection of a variety of human cells that bore those surface antigens with an ecotropic virus in vitro (Roux et al. , 1989)
Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb (Tooza, 1981) As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system This group of viruses is easy to grow and manipulate, and exhibit a broad host range in vitro and in vivo In lyrically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus
The El region of the genome includes El A and E1B which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular genes E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, e.g. DNA-binding protein, DNA polymerase, and a terminal protein that primes replication E3 gene products prevent cytolysis by cytotoxic T cells and tumor necrosis factor and appear to be important for viral propagation Functions associated with the E4 proteins include DNA replication, late gene expression, and host cell shutoff The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred The major late promoter (MLP) exhibits high efficiency during the late phase of the infection (Stratford-Perricaudet and Perricaudet, 1991)
As only a small portion of the viral genome appears to be required in cis (Tooza, 1981), adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells Ad 5 -transformed human embryonic kidney cell lines (Graham, et al, 1977) have been developed to provide the essential viral proteins in trans. The inventor thus reasoned that the characteristics of adenoviruses rendered them good candidates for use in targeting cancer cells in vivo (Grunhaus & Horwitz, 1992)
Particular advantages of an adenovirus system for delivering foreign proteins to a cell include (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA, (ii) the structural stability of recombinant adenoviruses, (iii) the safety of adenoviral
administration to humans, £nd (iv) lack of any known association of adenoviral infection with cancer or malignancies, (v) the ability to obtain high titers of the recombinant virus, and (vi) the high infectivity of Adenovirus
Further advantages of adenovirus vectors over retroviruses include the higher levels of gene expression Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences Because adenovirus transforming genes in the El region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible (Grunhaus & Horwitz, 1992)
In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus which is rendered replication-incompetent by deletion of a portion of its genome, such as El, and yet still retains its competency for infection Sequences encoding relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome For example, adenoviruses deleted in both El and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293 cells (Stratford-Perricaudet and Perricaudet, 1991) Surprisingly persistent expression of transgenes following adenoviral infection has also been reported
Adenovirus-mediated gene transfer has recently been investigated as a means of mediating gene transfer into eukaryotic cells and into whole animals For example, in treating mice with the rare recessive genetic disorder ornithine transcarbamylase (OTC) deficiency, it was found that adenoviral constructs could be employed to supply the normal OTC enzyme Unfortunately, the expression of normal levels of OTC was only achieved in 4 out of 17 instances (Stratford-Perricaudet et al, 1990) Therefore, the defect was only partially corrected in most of the mice and led to no physiological or phenotypic change These type of results therefore offer little encouragement for the use of adenoviral vectors in cancer therapy
Attempts to use adenovirus to transfer the gene for cystic fibrosis transmembrane conductance regulator (CFTR) into the pulmonary epithelium of cotton rats have also
been partially successful, although it has not been possible to assess the biological activity of the transferred gene in the epithelium of the animals (Rosenfeld et al, 1992). Again, these studies demonstrated gene transfer and expression of the CFTR protein in lung airway cells but showed no physiologic effect. In the 1991 Science article, Rosenfeld et al. showed lung expression of al-antitrypsin protein but again showed no physiologic effect. In fact, they estimated that the levels of expression that they observed were only about 2% of the level required for protection of the lung in humans, i.e., far below that necessary for a physiologic effect.
The gene for human al-antitrypsin has been introduced into the liver of normal rats by intraportal injection, where it was expressed and resulted in the secretion of the introduced human protein into the plasma of these rats (Jaffe et al, 1992). However, and disappointingly, the levels that were obtained were not high enough to be of therapeutic value.
These type of results do not demonstrate that adenovirus is able to direct the expression of sufficient protein in recombinant cells to achieve a physiologically relevant effect, and they do not, therefore, suggest a usefulness of the adenovirus system for use in connection with cancer therapy. Furthermore, prior to the present invention, it was thought that p53 could not be incorporated into a packaging cell, such as those used to prepare adenovirus, as it would be toxic. As E1B of adenovirus binds to p53, this was thought to be a further reason why adenovirus and p53 technology could not be combined.
Other viral vectors may be employed as expression constructs in the present invention. Vectors derived from viruses such as vaccinia virus (Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al, 1988) adeno-associated virus (AAV) (Ridgeway, 1988; Baichwal and Sugden, 1986; Hermonat and Muzycska, 1984) and herpes viruses may be employed. These viruses offer several attractive features for various mammalian cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden,
1986; Coupar et al, 1988; Horwich et al, 1990).
With the recent recognition of defective hepatitis B viruses, new insight was gained into the structure-function relationship of different viral sequences in vitro studies showed that the virus could retain the ability for helper-dependent packaging and reverse transcription despite the deletion of up to 80% of its genome (Horwich et al, 1990) This suggested that large portions of the genome could be replaced with foreign genetic material The hepatotropism and persistence (integration) were particularly attractive properties for liver-directed gene transfer Chang et al. recently introduced the chloramphenicol acetyltransferase (CAT) gene into duck hepatitis B virus genome in the place of the polymerase, surface, and pre-surface coding sequences It was cotransfected with wild-type virus into an avian hepatoma cell line Culture media containing high titers of the recombinant virus were used to infect primary duckling hepatocytes Stable CAT gene expression was detected for at least 24 days after transfection (Chang et al, 1991)
2 Alternative Methods for Gene Delivery In order to effect expression of therapeutic constructs according to the present invention, the expression vector must be delivered into a cell As described above, one mechanism for delivery is via viral infection where the expression vector is encapsidated in an infectious virus particle
Several non-viral methods for the transfer of expression vectors into cultured mammalian cells also are contemplated by the present invention These include calcium phosphate precipitation (Graham and Van Der Eb, 1973, Chen and Okayama, 1987, Rippe et al, 1990) DEAE-dextran (Gopal, 1985), electroporation (Tur-Kaspa et al, 1986, Potter et al, 1984), direct microinjection (Harland and Weintraub, 1985), DNA-loaded liposomes (Nicolau and Sene, 1982, Fraley et al, 1979) and lipofectamine-DNA complexes, cell sonication (Fechheimer et al, 1987), gene bombardment using high velocity microprojectiles (Yang et al, 1990), polycations (Boussif et al, 1995) and receptor-mediated transfection (Wu and Wu, 1987, Wu and Wu, 1988) Some of these techniques may be successfully adapted for in vivo or ex vivo use
In one embodiment .of the invention, the adenoviral expression vector may simply consist of naked recombinant vector Transfer of the construct may be performed by any of the methods mentioned above which physically or chemically permeabilize the cell membrane For example, Dubensky et al. (1984) successfully injected polyomavirus DNA in the form of CaPO4 precipitates into liver and spleen of adult and newborn mice demonstrating active viral replication and acute infection Benvenisty and Neshif (1986) also demonstrated that direct intraperitoneal injection of CaPO precipitated plasmids results in expression of the transfected genes It is envisioned that DNA encoding an p53 construct may also be transferred in a similar manner in vivo
Another embodiment of the invention for transferring a naked DNA expression vector into cells may involve particle bombardment This method depends on the ability to accelerate DNA coated microprojectiles to a high velocity allowing them to pierce cell membranes and enter cells without killing them (Klein et al, 1987) Several devices for accelerating small particles have been developed One such device relies on a high voltage discharge to generate an electrical current, which in turn provides the motive force (Yang et al, 1990) The microprojectiles used have consisted of biologically inert substances such as tungsten or gold beads
Selected organs including the liver, skin, and muscle tissue of rats and mice have been bombarded in vivo (Yang et al, 1990, Zelenin et al, 1991) This may require surgical exposure of the tissue or cells, to eliminate any intervening tissue between the gun and the target organ DNA encoding a p53, p300 or c-Abl construct may be delivered via this method
In a further embodiment of the invention, the expression vector may be entrapped in a liposome Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium Multilamellar liposomes have multiple lipid layers separated by aqueous medium Liposomes form spontaneously when phospholipids are suspended in an excess of aqueous solution The lipid components undergo self-rearrangement before the formation of closed structures and entrap water and
dissolved solutes between the lipid bilayers (Ghosh and Bachhawat, 1991) Also contemplated are lipofectamine-DNA complexes
Liposome-mediated polynucleotide delivery and expression of foreign DNA in vitro has been very successful Wong et al. (1980) demonstrated the feasibility of liposome-mediated delivery and expression of foreign DNA in cultured chick embryo,
HeLa and hepatoma cells Nicolau et al. (1987) accomplished successful liposome-mediated gene transfer in rats after intravenous injection
In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus (HVJ) This has been shown to facilitate fusion with the cell membrane and promote cell entry of liposome-encapsulated DNA (Kaneda et al, 1989) In other embodiments, the liposome may be complexed or employed in conjunction with nuclear non-histone chromosomal proteins (HMG-1) (Kato et al, 1991) In yet further embodiments, the liposome may be complexed or employed in conjunction with both HVJ and HMG-1 In that such expression vectors have been successfully employed in transfer and expression of a polynucleotide in vitro and in vivo, then they are applicable for the present invention Where a bacteriophage promoter is employed in the DNA construct, it also will be desirable to include within the liposome an appropriate bacteriophage polymerase
Another mechanism for transferring expression vectors into cells is receptor-mediated delivery This approach takes advantage of the selective uptake of macromolecules by receptor-mediated endocytosis in almost all eukaryotic cells Because of the cell type-specific distribution of various receptors, the delivery can be highly specific (Wu and Wu, 1993) Receptor-mediated gene targeting vehicles generally consist of two components a cell receptor-specific ligand and a DNA-binding agent Several ligands have been used for receptor-mediated gene transfer The most extensively characterized ligands are asialoorosomucoid (ASOR) (Wu and Wu, 1987) and transferrin (Wagner et al, 1993) Recently, a synthetic neoglycoprotein, which recognizes the same receptor as ASOR, has been used as a gene delivery vehicle (Ferkol et al, 1993, Perales
et al, 1994) and epidermaj growth factor (EGF) has also been used to deliver genes to squamous carcinoma cells (Myers, EPO 0273085)
In other embodiments, the delivery vehicle may comprise a ligand and a liposome For example, Nicolau et al. (1987) employed lactosyl-ceramide, a galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin gene by hepatocytes Thus, it is feasible that an adenoviral expression vector also may be specifically delivered into a cell type such as lung, epithelial or tumor cells, by any number of receptor-ligand systems, with or without liposomes For example, epidermal growth factor (EGF) may be used as the receptor for mediated delivery of p53, p300 or cAbl construct in many tumor cells that exhibit upregulation of EGF receptor Mannose can be used to target the mannose receptor on liver cells Also, antibodies to CD 5 (CLL), CD22 (lymphoma), CD25 (T-cell leukemia) and MAA (melanoma) can similarly be used as targeting moieties
In certain embodiments, gene transfer may more easily be performed under ex vivo conditions Ex vivo gene therapy refers to the isolation of cells from an animal, the delivery of a polynucleotide into the cells, in vitro, and then the return of the modified cells back into an animal This may involve the surgical removal of tissue/organs from an animal or the primary culture of cells and tissues Anderson et al. , U S Patent 5,399,346, and incorporated herein in its entirety, disclose ex vivo therapeutic methods During ex vivo culture, the expression vector can express the p53 construct Finally, the cells may be reintroduced into the original animal, or administered into a distinct animal, in a pharmaceutically acceptable form by any of the means described below
D. Treatment of p53-Negative Cancers using p53 and c-Abl
A patient presenting a tumor that does not express wild-type p53 will be treated with a combination of p53 and c-Abl and/or p300 The patient will be treated with a pharmaceutically acceptable form of the c-Abl and/or p300 genes or gene products, as described above, and in addition, will be treated with a p53 gene or gene product Again, a typical treatment regimen will involve repeated administrations over a six week period During
this time, the tumor will be monitored for absence of tumor progression, response or toxicity and the doses adjusted accordingly
E. Combination Therapy Tumor cell resistance to DNA damaging agents represents a major problem in clinical oncology One goal of current cancer research is to find ways to improve the efficacy of chemo- and radiotherapy by combining it with alternative therapies For example, the herpes simplex thymidine kinase gene, when delivered to brain tumors by a retroviral vector system, successfully induced susceptibility to the antiviral agent ganciclovir (Culver, et al. , 1992) In the context of the present invention, it is contemplated that c-Abl p300 therapy could be used similarly in conjunction with chemo- or radiotherapeutic intervention It also may prove effective to combine c-Abl/p300 therapy with immunotherapy
To kill tumor cells or reduce their proliferation, using the methods and compositions of the present invention, one would generally contact a "target" cell with (i) radiation or a chemotherapeutic and (ii) a therapeutic protein or gene These compositions would be provided in a combined amount effective to kill or inhibit proliferation of the cell This process may involve contacting the cells with c-Abl, p300 and p53 protein or gene, at the same time This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell with two distinct compositions or formulations, at the same time, wherein one composition includes c-Abl protein or gene and/or p300, and the other includes the p53 protein or gene
Alternatively, the protein or gene therapy treatment may precede or follow the standard chemo- or radiotherapy treatment by intervals ranging from minutes to weeks In embodiments where the other agent and an expression construct are applied separately to the cell, one generally would ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell In such instances, it is contemplated that one would contact the cell with both modalities within about 12-24 hours of each other and, more
preferably, within about 6-12. hours of each other, with a delay time of only about 12 hours being most preferred In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations
It also is conceivable that more than one administration of either c-Abl or p300 genes or proteins, and optionally p53 genes or proteins, with the other agent will be desired Various combinations may be employed, where c-Abl, and/or p300, and optionally p53 will be "A" and the other agent is "B", as exemplified below
A/B/A B/A/B B/B/A A/A B B/A/A A/B/B B/B/B/A B/B/A B
A A/B/B A/B/A/B A/B/B/A B/B/A/A B/A/B/A B/A/A/B B/B/B/A
A/A/A/B B/A A/A A/B/A/A A/A/B/A A/B/B/B B/A/B/B B/B/A B
Other combinations are contemplated Again, to achieve cell killing, both agents are delivered to a cell in a combined amount effective to kill the cell
Agents or factors suitable for use in a combined therapy are any chemical compound or treatment method that induces DNA damage when applied to a cell Such agents and factors include radiation and waves that induce DNA damage such as, γ-irradiation, X-rays, UV-irradiation, microwaves, electronic emissions, and the like A variety of chemical compounds, also described as "chemotherapeutic agents," function to induce DNA damage, all of which are intended to be of use in the combined treatment methods disclosed herein
Chemotherapeutic agents contemplated to be of use, include, e.g., adriamycin, 5-fluorouracil (5FU), etoposide (VP-16), camptothecin, actinomycin-D, mitomycin C, cisplatin (CDDP) and even hydrogen peroxide The invention also encompasses the use of a combination of one or more DNA damaging agents, whether radiation-based or actual compounds, such as the use of X-rays with cisplatin or the use of cisplatin with etoposide In certain embodiments, the use of
cisplatin in combination with a c-Abl or p300 expression construct is particularly preferred as this compound
In treating cancer according to the invention, one would contact the tumor cells with an agent in addition to the expression construct This may be achieved by irradiating the localized tumor site with radiation such as X-rays, UV-light, γ-rays or even microwaves Alternatively, the tumor cells may be contacted with the agent by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a compound such as, adriamycin, 5-fluorouracil, etoposide, camptothecin, actinomycin-D, mitomycin C, or more preferably, cisplatin The agent may be prepared and used as a combined therapeutic composition, or kit, by combining it with an expression construct, as described above
Agents that directly cross-link nucleic acids, specifically DNA, are envisaged to facilitate DNA damage leading to a synergistic, antineoplastic combination with c-Abl and/or p300 Agents such as cisplatin, and other DNA alkylating agents may be used Cisplatin has been widely used to treat cancer, with efficacious doses used in clinical applications of 20 mg/m2 for 5 days every three weeks for a total of three courses Cisplatin is not absorbed orally and must therefore be delivered via injection intravenously, subcutaneously, intratumorally or intraperitoneally
Agents that damage DNA also include compounds that interfere with DNA replication, mitosis and chromosomal segregation Such chemotherapeutic compounds include adriamycin, also known as doxorubicin, etoposide, verapamil, podophyllotoxin, and the like Widely used in a clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m2 at 21 day intervals for adriamycin, to 35-50 mg/m2 for etoposide intravenously or double the intravenous dose orally
Agents that disrupt the synthesis and fidelity of nucleic acid precursors and subunits also lead to DNA damage As such a number of nucleic acid precursors have been developed
Particularly useful are agents that have undergone extensive testing and are readily available
As such, agents such as 5-fluorouracil (5-FU), are preferentially used by neoplastic tissue, making this agent particularly useful for targeting to neoplastic cells Although quite toxic, 5- FU, is applicable in a wide range of carriers, including topical, however intravenous administration with doses ranging from 3 to 15 mg/kg/day being commonly used
Other factors that cause DNA damage and have been used extensively include what are commonly known as γ-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation It is most likely that all of these factors effect a broad range of damage DNA, on the precursors of DNA, the replication and repair of DNA, and the assembly and maintenance of chromosomes Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 weeks), to single doses of 2000 to 6000 roentgens Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells
The skilled artisan is directed to "Remington's Pharmaceutical Sciences" 15th Edition, chapter 33, in particular pages 624-652 Some variation in dosage will necessarily occur depending on the condition of the subject being treated The person responsible for administration will, in any event, determine the appropriate dose for the individual subject Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards
The inventors propose that the regional delivery of expression constructs to patients will be a very efficient method for delivering a therapeutically effective gene to counteract the clinical disease Similarly, the chemo- or radiotherapy may be directed to a particular, affected region of the subjects body Alternatively, systemic delivery of expression construct and/or the agent may be appropriate in certain circumstances, for example, where extensive metastasis has occurred
F. Pharmaceutical Compositions and Routes of Administration
Aqueous compositions of the present invention will have an effective amount of a compound that increases the expression of wild-type p53, for example p300 or c-Abl gene products or p300 or c-Abl gene constructs. Such compositions will generally be dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium. Also included in various embodiments of the present invention are standard chemotherapeutics in their various pharmaceutical forms.
The phrases "pharmaceutically or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or human, as appropriate. As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredients, its use in the therapeutic compositions is contemplated. Supplementary active ingredients, such as other anti-cancer agents, can also be incorporated into the compositions.
In addition to the compounds formulated for parenteral administration, such as those for intravenous or intramuscular injection, other pharmaceutically acceptable forms include, e.g. , tablets or other solids for oral administration; time release capsules; and any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like.
The active compounds of the present invention will often be formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, sub-cutaneous, or even intraperitoneal routes. The preparation of an aqueous composition that contains a compound or compounds that increase the expression of wild-type p53 will be known to those of skill in the art in light of the present disclosure. Typically, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the
addition of a liquid prior to injection can also be prepared, and the preparations can also be emulsified
In certain aspects of the invention, compounds may be injected directly into a tumor In other aspects, the route of delivery is by a slow drip into the circulatory system of the patient
Solutions of the active compounds as free base or pharmacologically acceptable salts can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, formulations including sesame oil, peanut oil or aqueous propylene glycol, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions In all cases the form must be sterile and must be fluid to the extent that easy syringability exists It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi
The active compounds may be formulated into a composition in a neutral or salt form Pharmaceutically acceptable salts, include the acid addition salts (formed with the free amino groups of the protein) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like
The carrier can also be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene
glycol, and the like), suitable mixtures thereof, and vegetable oils The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial ad antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
In certain cases, the therapeutic formulations of the invention could also be prepared in forms suitable for topical administration, such as in cremes and lotions. These forms may be used for treating skin-associated diseases, such as various sarcomas.
Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, with even drug release capsules and the like being employable.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for
intravenous, intramuscular, subcutaneous and intraperitoneal administration In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure For example, one dosage could be dissolved in 1 mL of isotonic NaCl solution and either added to 1000 mL of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580) Some variation in dosage will necessarily occur depending on the condition of the subject being treated The person responsible for administration will, in any event, determine the appropriate dose for the individual subject
G. Kits
All the essential materials and reagents required for determining wild-type p53 in a sample or for increasing the expression of wild-type p53 using c-Abl and p300 in tumor cells may be assembled together in a kit When the components of the kit are provided in one or more liquid solutions, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being particularly preferred
For the detection of wild-type p53, the kit may contain materials for PCR analyses, such primers, buffers and appropriate solvents Alternatively, if the detection is via immunologic means, the kit may contain antibodies directed to the p53, secondary antibodies that binding primary antibodies, labels or signal generating compounds (either conjugated or unconjugated) and various reagents for the generation and detection of signals
For in vivo use, an inducer of wild-type p53 expression, alone or in combination with, a expression vectors may be formulated into a single or separate pharmaceutically acceptable syringeable composition In this case, the container means may itself be an inhalant, syringe, pipette, eye dropper, or other such like apparatus, from which the formulation may be applied to an infected area of the body, such as the lungs, injected into an animal, or even applied to and mixed with the other components of the kit
The components of these kits may also be provided in dried or lyophilized forms When reagents or components are provided as a dried form, reconstitution generally is by the addition of a suitable solvent It is envisioned that the solvent also may be provided in another container means The kits of the invention may also include an instruction sheet defining administration of wild-type p53 and c-Abl gene therapy agents, or explaining the assays for determining p53 levels in samples
The kits of the present invention also will typically include a means for containing the vials in close confinement for commercial sale such as, e.g., injection or blow-molded plastic containers into which the desired vials are retained Irrespective of the number or type of containers, the kits of the invention also may comprise, or be packaged with, an instrument for assisting with the injection/administration or placement of the ultimate complex composition within the body of an animal Such an instrument may be an inhalant, syringe, pipette, forceps, measured spoon, eye dropper or any such medically approved delivery vehicle Other instrumentation includes devices that permit the reading or monitoring of reactions in vitro
H. Examples
The following examples are included to demonstrate preferred embodiments of the present invention It should be appreciated by those of skill in the art that that techniques disclosed in the examples which follow represent techniques discovered by the inventors to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar results without departing from the spirit and scope of the invention
Example 1: Role for c-Abl in Growth Arrest Response to DNA Damage
METHODS Transient transfections were done with lipofectamine (GIBCO-
BRL) Cells were collected 48 h after transfection Luciferase was assayed with an
enhanced luciferase assay kit (1800K, Analytical Luminescent) Histone HI kinase was assayed as described
Human MCF-7 breast cancer cells (p53+/+) were treated with 5 Gy IR at room temperature with a Gammacell 1000 (Atomic Energy of Canada) with a 187Cs source emitting at a fixed dose rate of 0 76 Gy min Lysates were prepared in 0 5% NP-40 lysis buffer as described MCF-7/pSR and MCF-7/c-Abl (K-R) cells were blocked at Gl/S phase by a 12 h treatment with 10 μM aphidicolin Cells were then washed, irradiated and fed with fresh medium containing 10% FCS
Asynchronous populations of abl+/+ and abl' MEFs (Tybulewicz et al, 1991) were exposed to IR and the percentage of cells in S phase assessed at 20 h BrdU was added 30 min before collection Cells were stained for DNA content with propidium and for DNA synthesis with a fluorescein conjugated anti-BrdU antibody (Boehringer Mannheim)
RESULTS The product of the c-Abl gene is a non-receptor tyrosine kinase that is localized to the nucleus and cytoplasm Ionizing radiation (IR) activates c-Abl Similar results were obtained with the alkylating agents cisplatinum and mitomycin C Cells deficient in c-Abl fail to activate Jun kinase (JNK/SAP kinase) following IR or alkylating agent exposure and that reconstitution of c-Abl in these cells restores that response In contrast, the stress response to tumor necrosis factor is stimulated by a c-Abl-independent mechanism These findings indicate that c-Abl is involved in the stress response to DNA-damaging agents
In addition to sharing structural features with members of the src family, c-Abl contains actin binding and DNA binding domains The finding that c-Abl associates with the retinoblastoma (Rb) protein has suggested a potential role for c-Abl in regulating the cell cycle (Welch and Wang, 1993) Other studies have shown that overexpression of c-Abl induces an arrest in Gi phase (Sawyers etal, 1994, Mattioni et al, 1995) Phosphorylation of c-Abl on multiple sites by p34cdc2 during mitosis has also supported a role in G2 phase (Kipreos and
Wany, 1990) The phosphorylation of c-Abl in mitotic cells inhibits DNA binding (Kipreos
and Wang, 1992) While these findings have suggested that c-Abl contributes to regulation of the cell cycle, the present studies demonstrate that c-Abl is activated by DNA-damaging agents DNA damage could dissociate c-Abl from a complex with other proteins and thereby contribute to interactions with potential substrates In this context, binding of c-Abl to the first Crk SH3 domain targets phosphorylation of c-Crk on Tyr221 (Feller et al, 1994, Ren et al, 1994, Feller et al, 1994) Since DNA damage is associated with arrest of cells in Gi and G2 phases, c-Abl activation could play a role in regulating these responses to genotoxic stress Alternatively, while overexpression of c-Abl arrests cells in Gi phase, activation of c-Abl by DNA damage may regulate distinct stress pathways that include SAP kinase
To determine whether c-Abl affects the function of p53, MCF-7 cells were co- transfected with a construct containing the luciferase gene driven by a p53 enhancer from the MDM2 promoter (Barak et al, 1994), and vectors expressing wild-type c-Abl, a kinase-inactive K(290)R mutant (Sawyers et al, 1994), or a kinase-active mutant, designated ΔPro4 which is deleted at the p53-binding domain (Goga et al, 1995) Co- transfections of the reporter with wild-type or kinase-inactive c-Abl (K-R), but not c- AblΔPro4 resulted in induction of luciferase activity (FIG 1A) By contrast, c-Abl expression had no detectable effect on activation of an SV40-luciferase construct (FIG la) As transcription of p21 is regulated by p53 (ref 6), the transfection of cells with c- Abl to induce p21 was investigated It was found that p21 expression increased in the c-
Abl and c-Abl (K-R), but not the c-AblΔPro4 transfectants (FIG IB) Despite induction of p21, which is an inhibitor of Cdk2 (refs 7-10), by both wild-type c-Abl and c-Abl (K- R), Cdk2 was downregulated only in cells transfected with wild-type c-Abl (FIG 1C), which correlates with the ability of wild-type c-Abl, but not c-Abl (K-R) or c-AblΔPro4 to inhibit growth in fibroblasts and MCF-7 cells These findings suggest that the kinase activity and p53-binding domain of c-Abl are involved in downregulation of Cdk2 and thus in growth arrest, and that such effects are not exclusively mediated by activation of p21
To determine the involvement of c-Abl in DNA-damage-dependent growth arrest
MCF-7 cells were prepared to stably express the dominant-negative c-Abl (K-R)2, which
effectively inhibits the increase in c-Abl kinase activity induced by ionizing radiation control cells (FIG 2A) Irradiation of MCF-7/pSR or MCF-7/c-Abl (K-R) cells caused an increase in p53, p21 and GADD45, but not in c-Myc (which is not dependent on p53) (FIG 2B), there was also increased binding of p21 to Cdk2 in MCF-7/pSR and in MCF- 7/c-Abl (K-R) cells (FIG 2C) Although Cdk2 was downregulated in irradiated MCF- 7/pSR cells, there was little effect on Cdk2 activity in MCF-7/c-Abl (K-R) cells (FIG 2D) These results indicate that c-Abl kinase is not required for transactivation of p21 and GADD45 by p53 in response to DNA damage, but is required for Cdk2 downregulation
The role of c-Abl in growth arrest induced by ionizing radiation was tested by the ability of irradiated MCF-7/pSR and MCF-7/c-Abl (K-R) cells to reduce the number of cells in S phase Using bromo-deoxyuridine (BrdU) labeling and bivariate fluorescence- activated cell-sorting (FACS) analysis, it was found that more irradiated MCF-7/pSR cells arrested in Gl compared with controls (FIG 3 A) Only 15% of cells were in S phase 24h after receiving 5 Gy radiation compared with untreated cells However, irradiated MCF- 7/c-Abl (K-R) cells were less affected, with the S-phase population being 45%> of untreated samples (FIG 3 A) Similar results were obtained with two independently isolated MCF-7/c-Abl (K-R) clones (FIG 3B) To confirm the link between c-Abl and radiation induced growth arrest, mouse embryo fibroblasts (MEFs) deficient in c-Abl (abl
' mice with targeted disruption of the c-abl gene) were studied (FIG 3C) Wild-type MEFs after 5 Gy radiation had an S-phase population that was 45% of that for untreated cells (FIG 3D) By contrast, irradiated abl ' MEFs had more than 70%> of cells in S phase compared with controls (FIG 3D) Exposure of the wild-type and abl'' MEFs to 20 Gy radiation partially inhibited arrest in Gl in the abl ' cells, indicating that the c-Abl kinase function is necessary for radiation-induced Gl arrest
As c-Abl and p53 bind together in vitro, the inventors determined whether they were associated in irradiated cells No p53 was detected in anti-c-Abl immunoprecipitates from MCF-7/pSR cells that had not been irradiated (FIG 4A), but binding of c-Abl and p53 was evident at 30 min and maximal at 3-5h after irradiation (FIG 4 A) The small
amount of constitutive binding of c-Abl to p53 found in MCF-7/c-Abl (K-R) cells was stimulated by irradiation (FIG 4A)
To investigate further the role of p53 in growth regulation by c-Abl, p53 ' fibroblasts were transfected with wild-type c-Abl and c-Abl (K-R) Analysis of p21 levels and Cdk2 activity failed to reveal any effect with either vector (FIG 4B) However, Cdk2 was downregulated in p53+/+ fibroblasts after transfection with wild-type c-Abl, but no c-Abl (K-R) (FIG 4B) These results show that c-Abl kinase inhibits Cdk2 by a p53- dependent mechanism The inventors found that the effect on Cdk2 activity of irradiating abl cells did not decrease as much as in wild-type MEFs (FIG 4C) In p21''' fibroblasts, it was found that p21 only partially mediates the action of p53 in arresting radiation- damaged cells in Gl (refs 12, 13) In support of previous findings, expression of c-Abl (K-R) had no effect on Cdk2 activity in p2l '' or p21+/+ cells (FIG 4D), whereas transfection of wild-type c-Abl into p21'' cells inhibited Cdk2 (FIG 4D) and growth, indicating that these effects of c-Abl depend on p53 but not p21 It is possible, however, that growth arrest following transfection with c-Abl inhibits Cdk2 activity
These results, obtained using a dominant-negative c-Abl mutant, suggest that c- Abl regulates growth in response to genotoxic stress Because c-Abl associates with the retinoblastoma protein Rb and overexpression of kinase-defective c-Abl abrogates Rb induced growth arrest, mutant c-Abl may prevent Gl arrest in response to DNA damage by inactivating Rb But as irradiated cells expressing c-Abl (K-R) do not arrest in Gl because Cdk2 is not inhibited, the effect probably occurs upstream of Rb The present inventors have demonstrated that c-Abl functions in the cellular response to DNA damage through p53-dependent pathways, confirmed by the failure of the c-AblΔPro4 mutant to bind p53 and downregulate Cdk2 and arrest growth It has also been shown that the kinase-defective c-Abl (K-R) mutant induces p53 transactivation but no Gl arrest although c-Abl stimulates the transcriptional activity of p53, as measured by expression of its target gene p21, a different mechanism is used by p21 in growth arrest because c-Abl mediated transactivation is kinase-independent and Cdk2 down-regulation
and growth arrest by the c-Abl kinase are p21 -independent These results support a novel c-Abl/p53 dependent, but p21 -independent, mechanism for the regulation of Cdk2
Example 2: Genotoxic Drugs Induce Interaction of c-Abl and p53
METHODS: Cell Culture - MCF-7 cells were cultured in Dulbecco's modified Eagle's medium (Sigma) containing 10%> heat-inactivated fetal bovine serum (Sigma), 2 mM L-glutamine, 100 units/ml penicillin, and 100 μg/ml streptomycin Null pSRαMSVtKneo, pSR MSVc-AblK(290)-RtKNeo (Sawyers et al, 1994), or E6Neo (Scheffner et al, 1990) vectors were stably introduced into cells by LipofectAMINE (Life
Technologies, Inc ) and selection in G418 The cells were treated with 10 μM ara-C (Sigma) or 10 μg/ml MMS (Sigma) Cell cycle analysis was performed as described (Yuan et al, 1996)
Immunoprecψitations and Immunoblot Analysis - Cell lysates were prepared as described (Yuan et al, 1996) and incubated with rabbit anti-Cdk2 (sc-163, Santa Cruz Biotechnology, San Diego, CA), mouse anti-c-Abl (Ab-3, Oncogene Science, Cambridge, MA), mouse anti-p53 (Ab-6, Oncogene Science) antibodies for 6-12 h at 4°C and then for 60 min with protein A-Sepharose For mouse antibodies, 10 μg/sample of rabbit anti-mouse IgG was added and incubated for 60 min before the addition of protein A beads The immune complexes were resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose filters and analyzed by immunoblotting using an ECL (Amersham Corp ) detection system
Kinase Assays - Cdk2 kinase assays were performed as described (Yuan et al,
1996) For c-Abl kinase assays, recombinant SHPTP1 protein (100 μg/ml) was used as substrate (Kharbanda et al, 1996), and the reaction was incubated for 30 min at 30°C
RESULTS Treatment of NIH3T3 cells with Ara-C is associated with activation of the c-Abl kinase (Kharbanda et al, 1995b) To determine whether the activation of c-Abl by genotoxic drugs is associated with growth arrest, the inventors prepared MCF-7
cells that stably express a dominant negative, kinase-inactive c-Abl (K290R) mutant (Sawyers et al, 1994) Treatment of control MCF-7/pSR cells with ara-C was associated with increases in c-Abl kinase activity By contrast, there was no detectable c-Abl activity in untreated or ara-C-treated MCR-7/c-Abl(K-R) cells
Other studies have demonstrated that c-Abl binds to p53 in vitro (Goga et al,
1996) Consequently, it was asked whether ara-C induces an interaction between c-Abl and p53 in vivo As a control, the inventors also prepared cells that express the human papillomavirus E6 protein to promote degradation of p53 (Scheffner et al, 1990) The MCF-7/E6 cells responded to ara-C with induction of c-Abl activity
In coimmunoprecipitation studies, there was no detectable p53 in the c-Abl immunoprecipitates from control MCF-7/pSR cells However, binding of c-Abl and p53 was detectable when MCF-7/pSR cells were treated with ara-C for 1 h The association of c-Abl and p53 was also increased by treatment of MCF-7/c-Abl(K-R), but not
MCF-7/E6, cells with ara-C These findings indicated that ara-C induces a c-Abl-p53 interaction independent of the c-Abl kinase function
Treatment of MCR-7/pSR and MCF-7/c-Abl(K-R) cells with ara-C was also associated with increases in p53 expression, while there was no apparent effect of this agent on p53 levels in MCF-7/E6 cells As transcription of p21 is regulated by p53 (El- Deiry et al, 1993), the MCF-7/pSR and MCF-7/Abl(K-R), but not the MCR-7/E6, cells responded to ara-C with induction of p21 expression p21 is an inhibitor of Cdk2 (El- Deiry et al, 1993, Gu et al, 1993, Harper et al, 1995) However, while p21 was induced in both MCF-7/pSR and MCF-7/c-Abl(K-R) cells and was bound to Cdk2 in both cell types, Cdk2 activity was down-regulated by ara-C treatment in only the MCF-7/pSR cells
As observed with ara-C, MMS exposure resulted in increased c-Abl activity in the MCF-7/pSR and MCF-7/E6 cells, but not the MCF-7/c-Abl(K-R) cells MMS increased binding of c-Abl and p53 in MCF-7/pSR and MCF-7/c-Abl(K-R), but not MCF-7/E6, cells MMS also induced the expression of p53 and p21 in only the MCF-7/pSR and
MCF-7/c-Abl(K-R) cells The MMS-induced increases in p21 levels were associated with binding of p21 to Cdk2 However, while Cdk2 activity was down-regulated in MMS-treated MCF-7/pSR cells, there was little effect of MMS on Cdk2 activity in the MCF-7/c-Abl(K-R) cells
The role of c-Abl in genotoxic drug-induced growth arrest was assessed by the ability of MMS to decrease populations of S phase cells The number of MCF-7/pSR cells in S phase at 9 h after MMS treatment was 67% of that obtained for untreated cells (Table I) By contrast, MMS-treated MCF-7/c-Abl(K-R) cells exhibited partial inhibition of the Gl response with an S phase population after treatment of over 80% of that for untreated cells (Table I) Similar findings were obtained with two independently isolated MCF-7/c-Abl(K-R) clones, while the Gi arrest response was almost completely abrogated in the MCF-7/E6 cells (Table I) These findings suggest that, as found for the down-regulation of Cdk2, c-Abl kinase activity is involved in MMS-induced Gl arrest by a p53-dependent mechanism
TABLE I MMS Induces p53-Mediated Gi Arrest by c-Abl Dependent Mechanisms
S phase cells
Transfectant Control Treated Treated Control
G
MCF-7/pSR 38 8 = 3 2 26 2 = 2 8 67 5
MCF-7/c-Abl(K-R)
Clone a 38 4 = 3 9 32 2 = 4 6 83 9
Clone b 37 9 = 3 0 30 6 = 2 8 80 7
MCF-7/E6 36 6 = 4 8 34 5 = 3 1 94 3
To substantiate the link between c-Abl and DNA damage-induced growth arrest, the effects of MMS on mouse embryo fibroblasts (MEFs) deficient in c-Abl (Abl-" ")
(Tybulewicz et al, 1991) were studied Wild type MEFs responded to MMS with induction of the c-Abl kinase, while there was no detectable c-Abl activity or protein in MMS-treated Abl"'" cells Both wild type and Abl"7" MEFs responded to MMS with increases in p53 and p21 levels These findings indicated that c-Abl is not necessary for DNA damage-induced increases in the transactivation function of p53 However, despite
induction of p21 in both cell types, Cdk2 activity was significantly down-regulated in MMS-treated wild-type, but not Abl"7", MEFs Wild-type MEFs also responded to MMS with Gl arrest The number of wild type MEFs in S phase at 9 h after MMS treatment was 51%) of that obtained for untreated cells (FIG 5) By contrast, MMS-treated Abl"/_ cells had an S phase population which was 71%> of that for untreated cells (FIG 5)
These findings suggest that c-Abl is involved in the down-regulation of Cdk2 and that the Gl arrest response involves mechanisms other than activation of p21
The present results demonstrate that treatment of cells with ara-C or MMS is associated with binding of c-Abl and p53 Similar findings have been obtained with the genotoxic topoisomerase inhibitors camptothecin and etoposide and with ionizing radiation exposure (Yuan et al, 1996) Thus, diverse types of DNA damage activate c-Abl (Kharbanda et al, 1996b, Kharbanda et al, 1995), and the interaction of c-Abl with p53 However, the finding that c-Abl binds to p53 following treatment of the MCF-7/c-Abl(K-R) cells with genotoxic agents indicates that activation of the c-Abl kinase is not necessary for the interaction Moreover, the demonstration that expression of p53 and p21 is increased in MMS-treated MCF-7/c-Abl(K-R) and Abl"7" cells suggests that c-Abl is not necessary for inducing certain transactivation functions of p53 following genotoxic stress Conversely, the findings that c-Abl is activated by DNA-damaging agents in MCF-7/E6 and p53"/_ cells indicates that p53 is dispensable for c-Abl activation
The present results also indicate that activation of the c-Abl kinase is necessary for the complete Gi arrest response to genotoxic drugs Induction of p21 expression and binding of this Cdk inhibitor to Cdk2 by genotoxic stress is insufficient for the complete down-regulation of Cdk2 Rather, findings indicate that induction of c-Abl kinase activity is also involved in the down-regulation of Cdk2 and growth arrest Recent work has shown that overexpression of kinase active, but not inactive, c-Abl in p21"7" fibroblasts is associated with down-regulation of Cdk2 and growth arrest (Yuan et al, 1996) In concert with these results is the demonstration that p53-dependent events can inhibit cell growth through p21 -independent mechanisms (Deng et al, 1995, Hirano et al, 1995,
Brugarolas et al, 1995) Taken together, these findings indicate that genotoxic agents
induce the down-regulation of Cdk2 and Gl arrest by a mechanism dependent on activation of c-Abl kinase and binding of c-Abl to p53, but independent of p21.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention.
REFERENCES
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference
Abbondanzo et al. , Breast Cancer Res. Treat., 16 182(no 151), 1990
Abou-Shoer, M , Ma, GE , et al. J. Nat. Prod, 56(6) 967-9, 1993
Aizu-Yokota et α/., Cancer Res., 55 1863-1868, 1995 Akiyama, T , Ishida, J , et al, J. Biol Chem., 262 5592-5595, 1987
Al-Khodairy, F and Carr, A M , EMBOJ., 11 1343-1350, 1992
Alfred et al, Breast Cancer Res. Treat., 16 182(no 149), 1990
Aruoma, O I , Halliwell, B , et al, Free Radicals Biol. Med 6 593-597, 1989
Atherton-Fessler, S , Parker, L L , et al, Mol. Cell. Biol, 13 1675-1685, 1993 Avantaggiati et al, EMBO J , 15 2236-2248, 1996
Baichwal and Sugden, "Vectors for gene transfer derived from animal DNA viruses Transient and stable expression of transferred genes," In: Kucherlapati R, ed Gene transfer New York Plenum Press, pp 117-148, 1986
Bannister and Kouzarides, Nature, 384 541-643, 1996 Barak, Y , Gottlieb, E , Juven-Gershon, T & Oren, M Genes & Development 8, 1739-
1749, 1994
Barbet, N C and Carr, A M , Nature, 364 824-827, 1993
Barnekow, A. and Gessler, M , EMBOJ., 5 701-705, 1986
Bartek, J , Vojtesek, B , Grand, R J A , Gallimore, P H & Lane, D P Oncogene 7, 101-108, 1992
Baskaran et α/., Proc. Nat 'l Acad. Sci. USA, 90 11167-11171, 1993
Benvenisty and Neshif, Proc. Nat'l Acad. Sci. USA, 83 9551-9555, 1986
Bhuyan, B K , Smith, K S , et al, Cancer Res., 52 5687-5692, 1992
Blagosklony et α/., Oncogene, 11 933-939, 1995 Bonni, A , Frank, D A , etal, Science, 262 1575-1579, 1993
Borrow et al, Nature Genet., 14 33-41, 1996
Boussifetα/., Proc. Nat'l Acad. Sci. USA, 92 7297-7301, 1995
Brach, M A , Hass, R , et al, I Clin. Invest. 88 691-695, 1991
Brown et al, Breast Cancer Res. Treat., 16 192(#191), 1990
Brugarolas et al , Nature, 977 552-557, 1995
Brugarolas, J , et al. Nature 377, 552-557, 1995 Buchdunger, E , Trinks, U , , Proc. Nat 'I Acad. Sci. USA, 91(6) 2334-8, 1994
Burgunder, J M , Varriale, A , et al., Eur. J Clin Pharmacol, 36 127-131, 1989
Cantley, L , Auger, K R , et al, Cell, 64 281-302 1991
Carrano, A V , Thompson, E H , et al , Mutat. Res., 63 175-178, 1979
Carter, R H , Park, D J , et al, Proc. Nat 'I Acad. Sci. USA, 88 2745-2749, 1991 Casey, et al, Oncogene, 6 1791-1797, 1991
Casillas, A , Hanekom, C , et al., J Biol. Chem., 266 19088-19094, 1991
Chan, T C , Chang, C J , et al, Biochem Biophys Res Commun, 30 (3) 193, 1993
Chang et al., Hepatology, 14 124 A, 1991
Chen and Okayama, Mol. Cell Biol, 7 2745-2752, 1987 Chen, J L , Proteau, P J , et al. , JNat Prod, 57(4) 524-7, 1994
Chomczynsky and Sacchi, Anal. Biochem., 162 156-169, 1987
Chou, J and Roizman, B , Proc. Nat 'l Acad. Sci. 89, pp 3266-3270, 1992
Coffin, "Retroviridae and their replication," In: Fields BN, Knipe DM, ed Virology New York Raven Press, pp 1437-1500, 1990 Coupar et al , Gene, 68 1 - 10, 1988
Culver et al , Science, 256 1550-1552, 1992
Cushman et al, J. Med. Chem., 38 2041-2049, 1995
Dai and Pendergost, Genes Dev., 9 2569-2582, 1995
Datta, R , Hallahan, D , et al, Biochemistry, 31 8300-8306, 1992b Datta, R , Rubin, E , et al, Proc. Nat'l Acad. Sci. USA, 89 10149-10153, 1992a
Datta, R , Taneja, N , et al. , Proc. Nat 'I Acad. Sci. USA, 90 2419-2422, 1993
Deng et al, Cell, 82 675-684, 1995
Deng, C , Zhang, P , Harper, J W , Elledge, S J & Leder, P Cell 82, 675-684 1995
Derijard, B , et al. Cell 76, 1025-1037, 1994 Desai, D , Gu, Y et al., Mol Biol. Cell, 3 571-582, 1992
Devary, Y , Gottlieb, R A , et al, Cell, 71 1081-1091, 1992
Dubensky <?t α/., røc. Nat'l Acad. Sci. USA, 81 7529-7533, 1984
Dulic, V , et al. Cell 76, 1.013-1023, 1994
Dusre, L , Covey, J M , et al, Chem. -Biol. Interactions, 71 63-78, 1989
Duyster et α/., roc. Nat 'l Acad. Sci. USA, 92 1555-1559, 1995
Eckner et al, Genes Dev., 10-2478-2490, 1996b Eckner et a , Mol. Cell Biol , 16-3454-3464, 1996a
El-Deiry et al, Cell, 75 817-825, 1993
El-Deiry et α/., Cell, 75 817-825, 1993
El-Deiry, W , et al Cell 75, 817-825, 1993
Engelberg, D , Klem, C , Martinetto, H , Struhl, KJ & Karin, M Cell 77, 381-390 1994 Enoch, T and Nurse, P , Cell, 60 665-673, 1990
EP 320 308
EP 329 822
Ewig, R A and Khon, K W , Cancer Res., 37 2114-2122, 1977
Featherstone, C and Russell, P , Nature, 349 808-811, 1991 Fechheimer et α/., røc. Nat 'l Acad. Sci. USA, 84 8463-8467, 1987
Feigner, VE et al. Proc. Nat 'l Acad. Sci. USA 84, 7413-7417, 1987
Feller, Knudsen, Hannafusa, EMBO J., 18 2341-2351, 1994
Feller, S M , Knudsen, B & Hanafusa, H EmboJ. 13, 2341-2351, 1994
Feller, S M , Ren, R , Hanafusa, H and Baltimore, D TIBS 19, 453-458, 1994 Ferkol et al, FASEBJ, 7 1081-1091, 1993
Fodor et al, Science, 251 767-773, 1991
Fotsis et α/., Nature, 368 237-239, 1994
Eraley et l, Proc. Nat'l Acad. Sci. USA, 76 3348-3352, 1979
Friedmann, Science, 244 1275-1281, 1989 Frohman, In PCR Protocols: A Guide To Methods And Applications, Academic Press,
N Y , 1990
Fujiwara et α/., Cancer Res., 54 2287-2291, 1994
Gazit, A , Yaish, P , etal, JMedChem, 32(10) 2344-52, 1989
GB 2 202 328 Geahlen, RL and McLaughlin, J L , Biochem Biophys Res Commun, 165(1) 241-5, 1989
Gee, C E , Griffin, J , etal, Proc. Nat'l Acad. Sci. USA, 83 5131-5135, 1986
Ghosh and Bachhawat, "Targeting of liposomes to hepatocytes," In: Wu G, Wu C ed Liver diseases, targeted diagnosis and therapy using specific receptors and ligands New York Marcel Dekker, pp 87-104, 1991
Gillespie, J , Dye, J F , et al, BrJ Cancer, 68(6) 1122-6, 1993 Goga et α/., Oncogene, 1 1 791-799, 1996
Goga, , et al Oncogene 11, 791-799, 1995
Gold, M R , Chan, V W -F , et al, J. Immunol, 148 2012-2017, 1992b
Gold, M R , Crowley, M T , et al, J. Immunol, 148 2012-2022, 1992a
Gopal, Mol. Cell Biol, 5 1188-1190, 1985 Gould, K and Nurse, P , Nature, 342 39-44, 1989
Gould, K L , Moreno, S , et al, Science, 250 1573-1576, (1990
Graham and van der Eb, Virology, 52 456-467, 1973
Graham et al., J Gen. Virol, 36 59-72, 1977
Grunhaus and Horwitz, Seminar in Virology, 3 237-252, 1992 Gu, Turek, Morgan, Nature, 366 707-710, 1993
Gu, Y , Turck, C & Morgan, D Nature 366, 707-710, 1993
Hacia et al, Nature Genetics, 14 441-447, 1996
Hall, E J In: Radiobiology for the Radiologist, 3rd Edition, ed Hall, E J (Lippincott, Philadelphia), pp 17-38, 1988 Hallahan, D , Sukhatme, V , et al. , Proc. Nat 'I Acad. Sci. USA 88 2156-2160, 1991
Hanks, S J , Quinn, A M et al, Science, 241 42-52, 1988
Harland and Weintraub, J. Cell Biol, 101 1094-1099, 1985
Harper et al, Mol. Biol Cell, 6 387-400, 1995
Harper, J W , et al. Mol Biol Cell 6, 387-400, 1995 Hartley, J A , Bingham, J P etal, Nucleic Acids Res., 20 3175-3178, 1992
Hartwell, L H and Weinert, T A Science, 246 629-634, 1989
Hempel, W M , Schatzman, R C et al, J. Immunol, 148 3021-3025, 1992
Hermonat and Muzycska, Proc. Nat'l Acad. Sci. USA, 81 6466-6470, 1984
Hidaka, H , Inagaki, M , et al, Biochemistry, 23 5036-5041, 1984 Hirano, Yamato, Tsuchida, Oncogene, 10 1879-1885, 1995
Hollstein, et al , Science 253 49-53 1991
Horwich, et al, J. Virol, 64 642-650, 1990
Hsu, C Y , Jacoski, M V , et.al, Biochem Pharmacol, 43(11) 2471-7, 1992
Hurley, L H , Reynolds, V L , et al, Science, 226 843-844, 1984
Jaffe et al, Nature Genetics 1 372-378, 1992
Jayasuπya, H , Koonchanok, N M , et al, JNat Prod, 55(5) 696-8, 1992 Kakeya, H , Imoto, M , et al. , FEBS Lett, 320(2) 169-72, 1993
K eάa et al, Science, 243 375-378, 1989
Kastan, M , Onyekware, O , et al, Cancer Res., 51 6304-6311, 1991
Kastan, M B , Zhan, Q , et al, Cell, 71 587-597, 1992
Katagiri, K , Katagiri, T , et al., J Immunol, 146 701-707, 1991 Kato et al. , J. Biol Chem. , 266 3361-3364, 1991
Kharbanda et al, J. Biol. Chem., 270 30278-30281, 1995b
Kharbanda et al, Nat 'l Acad. Sci. USA, 98 6898-6901, 1996
Kharbanda et al, Nature, 376 785-788, 1995a
Kharbanda, S , et al. Nature 376, 785-788, 1995 Khetaφal, V K , Markham, P M , et al. , Drug Metab Dispos, 22(2) 216-23, 1994
Kipreas and Wang, Science, 248 217-220, 1990
Kipreas and Wang, Science, 256 382-385, 1992
Kipreos, E T & Wang, J Y J Science 256, 382-385, 1992
Kipreos, E T & Wangm, J Y J Science 248, 217-220, 1990 Klein et al. , Nature, 327 70-73, 1987
Konopa, J Biochem. Pharmacol, 37 2303-2309, 1988
Kufe et al, Mol. Pharmacol, 26 126-134, 1984
Kufe et al, J. Biol. Chem., 255 8997-9000, 1980
Kwoh et al, Proc. Nat 'l Acad. Sci. USA, 86 1173, 1989 Kyriakis, J M , et al Nature 369, 156-160,1994
Lamer, A C , David, M , et al, Science, 261 1730-1733, 1993
Lau, C C and Pardee, A B , Proc. Nat'l Acad. Sci. USA, 79 2942-2946, 1982
Lock, R B and Ross, W E , Cancer Res., 50 3761-3766, 1990
Lowe, S W , Jacks, T , Housman, D E & Ruley, H R Proc. Nat 'l Acad. Sci. USA 91, 2026-2030, 1994
Major et al, Proc. Nat'l Acad. Sci. USA, 78 3235-3239, 1981
Matm et aL, Cell, 33 153-159, 1983
Mattioni et al, Oncogene, 10 1325-1333, 1995
Mattioni, T , Jackson, P K , Bchini-Hooft van Huijsduijnen, O & Picard, D Oncogene 10, 1325-1333, 1995
Mattioni, T , Jackson, P K , van Huijsduijnen, O B H & Picard, D Oncogene 10, 1325-1333, 1995
McWhirter and Wang, EMBO J., 12 1533-1546, 1993
Mercer, Critic. Rev. Eukar. Gene Express. 2 251-263, 1992
Merkel, L A , Rivera, E M , et al, Biochem Biophys Res Commun, 192(3) 1319-26, 1993
Milner and Watson, Oncogene, 5 1683-1690, 1990 Montenarh, Crit. Rev. Oncogen, 3 233-256, 1992
Moran, E , Curr. Opm. Genet. Dev., 3 63-70, 1993
Morgenstera, J F & Land, H Nucleic Acid Res 18, 3587-3596, 1990
Mosmann, J. Immunol. Methods, 65 55-63, 1983
Mukherjee, A B et al. Proc. Nat'l Acad. Sci. USA 75, 1361-1365, 1978 Mukhopadhyay et al. , Oncogene, 11 999- 1003 1995
Mukhopadyay and Roth, Cancer Res., 53 4362-4366, 1993
Muraoka et α/., Oncogene, 12 1565-1569, 1996
Murray, A , Nature, 341 14-15, 1989
Mustalin, T , and Altman, A , Oncogene 5 809-813, 1990 Myers, EPO 0273085
Nakamura, K , Hori, T , etal, Oncogene S, 3133-3139, 1993
Nakamura, S , Yanagi, S , et al, Eur. J. Biochem., 174 471-477, 1988
Nicolas and Rubenstein, "Retroviral vectors," In: Rodriguez RL, Denhardt DT, ed Vectors A survey of molecular cloning vectors and their uses Stoneham Butterworth, pp 493-513, 1988
Nicolau and Sene, Biochim. Biophys. Acta, 721 185-190, 1982
Nicolau etal, Methods Enzymol, 149 157-176, 1987
Nicolau, C et al. Proc. Nat'l Acad. Sci. USA 80, 1068-1072, 1983
Norbury, C , and Nurse, P., Ann. Rev. Biochem., 61 441-470, 1992 Nurse, P , Nature, 344 503-507, 1990
O'Connor, P M , Ferris, O , et al, Cell Growth & Differ., 3 43-52, 1992
Ogryzko et al, Cell, 87-953-959, 1996,
Oh ichi, M , Pang, L , et al. Biochemistry, 32(17) 4650-8, 1993
Ohno et al, Cancer Res., 48 1494-1498, 1988
Okabe, T , Yoshida, E , et al., 1 Antώiot, 47(3) 289-93, Mar 1994
Onoda, T , Iinuma, H , et al, J Nat Prod, 52 (6) 1252-7, 1989 Parker, L L , Atherton-Fessler, S , et al, EMBO J, 10 1255-1263, 1991
Parker, L L , Atherton-Fessler, S , etal, Proc. Nat'l Acad. Sci. USA, 89 2917-2921, 1992
Parker, L L , Atherton-Fessler, S , et al, EMBOJ, 10 1255-1263, 1991
Paskind etal, Virology, 67 242-248, 1975
PCT/US87/00880 PCT/US89/01025
Pear, W S , Nolan, G P , Scott, M L and Baltimore, D Proc. Nat 'l Acad. Sci. (USA) 90, 8392-8396, 1993
Pease et al, Proc. Nat 'l Acad. Sci. USA, 91 5022-5026, 1994
Vvcύzs et al, Proc. Nat 'l Acad. Sci 91 4086-4090, 1994 Pignon et al. , Hum. Mutat , 3 126- 132, 1994
Pines, J and Hunter, T , New Biol, 2 389-401, 1990
Pines, J , and Hunter, T , Cell, 58 833-846, 1989
Pleiman, C M , Clark, M R , et al, Mol. Cell. Biol, 13 5877-5887, 1993
Post and Roizman Cell, 25 227, 1981 Potter et al, Proc. Nat 'I Acad. Sci. USA, 81 7161-7165, 1984
Pulverer, B J , Kyriakis, J M , Avruch, J , Nikolakaki, E & Woodgett, R Nature 353, 670-674, 1991
Puri et al, EMBO J., 16 369-383, 1997
Rauth, G , Poschke, O , etal, EurJ Biochem, 204(2) 523-9, 1992 Ren et al, Genes Dev., 8 783-795, 1994
Ren, R , Ye, Z S & Baltimore, D Genes and Develop , 8, 783-795, 1994
Rewcastle, G W , Palmer, B D , etal, J Med Chem, 37(13) 2033-42, 1994
Ridgeway, "Mammalian expression vectors," In: Rodriguez RL, Denhardt DT, ed Vectors A survey of molecular cloning vectors and their uses Stoneham Butterworth, pp 467-492, 1988
Rippe etal, Mol. Cell Biol, 10 689-695, 1990
Roederer, M , Staal, F J T , et al, Proc. Nat 'I Acad. Sci. USA, 87 4884-4888, 1990
Rosenfeld et α/., Cell, 68 143-155, 1992
Rosenfeld et al, Science, 252 431-434, 1991
Roux et al, Proc. Nat'l Acad. Sci. USA, 86 9079-9083, 1989
Rowley, R , Subramani, S , et al, EMBO J, 11 1335-1342, 1992 Rubinstein et al. , J. Nat 'I Cancer Inst. , 82 1113 - 1120, 1990
Ruff- Jamison, S R , Chen, K et al, Science, 261, 1733-1736, 1993
Russell, P , and Nurse, P , Cell, 45 559-567, 1987
Saleem, A , Yuan, Z M , Kufe, D W & Kharbanda, S J , Immunol 154, 4150-4156, 1995
Sambrook et al, In Molecular Cloning: A Laboratory Manual, 2d Ed , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989
Sawyers et al, Cell, 77 121-131, 1994
Sawyers, C L , McLaughlin, J , Goga, A , Havilik, M & Witte, O Cell 77, 121-131, 1994
Sawyers, C L , McLaughlin, J , Goga, A , Havilik, M & Witte, O Cell 77, 121-131, 1994 Scheffher et al, Cell, 63 1129-1136, 1990
Schiestl, R H , Reynolds, P , et al, Mol. Cell. Biol, 9 182-1896, 1989
Schwartz, Carcmogenesis, 7 159-162, 1986
Sherman, M , Stone, R , et al. J. B ol Chem., 265 3320-3323, 1990
Sherman, S E & Lippard, S J Chem. Rev 87, 1153-1181, 1987 Sherman, S E and Lippard, S J , Chem. Rev., 87 1153-1181, 1987
Shi et al, Genes Dev., 9 2583-2597, 1995
Shoemaker et al, Nature Genetics 14 450-456, 1996
Shtivelman, E , Lifshitz, B , Gale, R P , Roe, B A and Canaani, E , Cell 47 277-284 1986
Smyth, M S , Stefanova, I , et al, JMedChem, 36(20) 3010-4, 1993b Smyth, M S , Stefanova, I , etal, JMedChem, 36(20) 3015-20, 1993a
Solomon, M J , Lee, T et al, Mol. Biol Cell, 3 13-27, 1992
Songyang, Z , etal. Nature 373, 536-539, 1995
Staal, F J T , Roederer, M , etal, Proc. Nat'l Acad. Sci. USA, 87 9943-9947, 1990
Stein, B , Rahmsdorf, H J , et al, Mol. Cell. Biol, 9 5169-5181, 1989 Steinmann, K E , Belinsky, G S , et al, Proc. Nat 'I Acad. Sci. USA, 88 6843-6847, 1991
Stratford-Perricaudet and .Perricaudet," Gene transfer into animals the promise of adenovirus," p 51-61, In: Human Gene Transfer, Eds, O Cohen-Haguenauer and M Boiron, Editions John Libbey Eurotext, France, 1991 Stratford-Perricaudet et al, Hum. Gene. Ther. 1 241-256, 1990 Sugata, D , Yamashita, K , et al, Biochem Biophys Res Commun, 194(1), 1993
Takahashi et al, Cancer Res 52 2340-2342, 1992 Tanaka, S , Okabe, T , et al. , Antibiot (Tokyo), 47(3) 297-300, 1994b Tanaka, S , Okabe, T , etal, J Antibiot (Tokyo), 47(3) 294-6, 1994a
Temin, "Retrovirus vectors for gene transfer Efficient integration into and expression of exogenous DNA in vertebrate cell genome," In. Kucherlapati R, ed Gene transfer
New York Plenum Press, pp 149-188, 1986 Thakkar, K , Geahlen, R E , et al, JMed Chem, 36(20) 2950-5, 1993 Tobey, R A , Nature, 254 245-247, 1975
Tomasz, M , Chawla, A K & Lipman, R Biochemistry 27, 3182-3187, 1988 Tomasz, M , Chawla, A K , et al, Biochemistry, 27 3182-3187, 1988
Tooze, "Molecular biology of DNA Tumor viruses", 2nd ed Cold Spring Harbor
Laboratory, Cold Spring Harbor, New York, 1991 Townsend and Cheng, Mol. Pharmacol, 32 330-339, 1987 Tur-Kaspa et /., Mol. Cell Biol, 6 716-718, 1986 Tybulewicz et al, Cell, 65 1153-1163, 1991
Tybulewicz, V L J , Crawford, C E , Jackson, P K , Bronson, R T & Mulligan, R C
Cell 65, 1153-1163, 1991 Tybulewicz, V L J , Crawford, C E , Jackson, P , Bronson, R T & Mulligan, R C Cell 65, 1153-1163, 1991 U S Patent 5,399,346
U S Patent 4,683,195 U S Patent 4,683,202 U S Patent 4,800,159 U S Patent 4,883,750 U S Patent 5,279,721
Uckun, F M , Schievan, G E , et al, Proc. Nat 'I Acad. Sci. USA, 90 252-256, 1993 Uckun, F M , Tuel-Ahlgren, L , et al, Proc. Nat 'I Acad. Sci. USA, 89 9005-9009, 1992a
Uehara, Y , Murakami, Y , et al, Cancer Res , 49 780-785, 1989
Umezawa, K and Imoto, M , Methods Enzymol, 201 379-85, 1991
Van Etten et al, Cell, 58 669-678, 1989
Van Etten, et al, J. Cell Biol, 124 325-340, 1994 Wagner et al , 1993, Science, 260 1510- 1513
Wag r et al, Science, 260 1510-1513, 1993
Wagner, R W , Matteucci, M D , Lewis, J G , Gutierrez, A J , Moulds, C and Froehler, B C , Science, 260, 1510-1513, 1993
Walker et al, Proc. Nat'lAcad. Sci. USA, 89 392-396 1992 Weinberg, "Tumor suppressor gene" Science 254 1 138-1 145, 1991
Weinert, T and Hartwell, L , Science, 241 317-322, 1988
Welch, P J & Wang, J Y J Cell 75, 779-790, 1993
Welch, P J & Wang, J Y J Mol. Cell. Biol 15, 5542-5551, 1995
Welch, P J & Wang, J Y Ce// 75, 779-790, 1993 Wen et al, EMBO J, 15 1583-1595, 1996
WO 88/10315
WO 89/06700
WO 90/07641
Wong et al, Gene, 10 87-94, 1980 Wong, T W and Goldberg, A R , J. Biol Chem., 259 8505-8512, 1984
Wu and Wu, J. Biol Chem., 262 4429-4432, 1987
Wu and Wu, Adv. Drug Delivery Rev., 12 159-167, 1993
Wu and Wu, Biochemistry, 27 887-892, 1988
Wu et l, Genomics, 4 560, 1989 Xiong, Y , et al. Nature 366, 701-704, 1993
Yamanashi, Y , Fukui, Y , et al, Proc. Nat'lAcad. Sci USA, 89 1118-1122, 1992
Yamanashi, Y , Fukushige, S , etal, Mol. Cell. Biol, 7 237-243, 1987
Yamanashi, Y , Mori, S , etal, Proc. Nat'lAcad. Sci. USA, 86 6538-6542, 1989
Yang et al, Nature, 382 319-324, 1996 Yang et al, Proc. Nat 'I Acad. Sci. USA, 87 9568-9572, 1990
Yoneda, T , Lyall, R M , et al, Cancer Res, 51(16) 4430-5, 1991
Yuan et al, Nature, 382 272-275, 1996
Yuan, Z -M , Kharbanda, S. & Kufe, D Biochemistry 34, 1058-1063 ,1995
Zelenin et α/., FEBS Lett., 280 94-96, 1991
Zioncheck, T F , Harrison, M L et al, J. Biol. Chem., 261 15637-15643, 1986
Claims
1. A method for increasing p53-mediated apoptosis in a tumor cell comprising the step of increasing the activity level of at least one of c-Abl and p300 in said tumor cell.
2. The method of claim 1, wherein said tumor cell is derived from a tissue selected from the group consisting of brain, lung, liver, spleen, kidney, lymph node, small intestine, blood cells, pancreas, colon, stomach, breast, endometrium, prostate, testicle, ovary, skin, head and neck, esophagus, bone marrow and blood tissue..
3. The method of claim 1, wherein the activity levels of both c-Abl and p300 are increased in said tumor cell.
4. The method of claim 1, wherein the activity level is increased by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor cell in an amount effective to increase p53-mediated apoptosis.
5. The method of claim 1, wherein the activity level is increased by providing at least one of a nucleic acid encoding c-Abl and a nucleic acid encoding p300 to said tumor cell, wherein said nucleic acid is operably linked to a promoter active in eukaryotic cells in an amount effective to increase p53-mediated apoptosis.
6. The method of claim 1, wherein the activity level is increased by providing an agent to said cell that increases the expression or stability of at least one of c-Abl and p300 in an amount effective to increase p53-mediated apoptosis.
7. The method of claim 4, wherein said polypeptide is delivered in a liposome.
8. The method of claim 5, wherein said nucleic acid is contained in an expression vector.
9 The method of claim 8, wherein said expression vector is a viral vector
10 The method of claim 9, wherein said viral vector is selected from the group consisting of herpesvirus, adenovirus, vaccinia virus, retrovirus and adeno-associated virus
1 1 The method of claim 10, wherein said nucleic acid is encapsulated in a viral particle
12 The method of claim 1, wherein said tumor cell is defective in p53, and said method further comprises providing to said tumor cell a nucleic acid encoding a wild- type p53 operably linked to a promoter active in eukaryotic cells
13 The method of claim 12, wherein said nucleic acid is contained in an expression vector
14 The method of claim 13, wherein said expression vector is a viral vector
15 The method of claim 14, wherein said viral vector is selected from the group consisting of herpesvirus, adenovirus, vaccinia virus, retrovirus and adeno-associated virus
16 The method of claim 1 , further comprising contacting said cell with ionizing radiation
17 The method of claim 1, further comprising contacting said cell with a chemotherapeutic agent
18 The method of claim 13, wherein said ionizing radiation is x-irradiation or γ- irradiation
19. The method of claim 14, wherein said chemotherapeutic agent is selected from the group consisting of mitomycin C, etoposide, genistin, cisplatin, 5-FU, adriamycin, doxorubicin, actinomycin D, verapamil, nitrosourea, ara-C and camptothecin.
20. A method for treating a patient having a tumor comprising the step of increasing the activity level of at least one of c-Abl and p300 in cells of said tumor.
21. The method of claim 20, wherein the activity level is increased by providing at least one of a c-Abl polypeptide and a p300 polypeptide to said tumor in an amount effective to increase p53-mediated apoptosis in cells thereof.
22. The method of claim 20 wherein the activity level is increased by providing at least one of a nucleic acid encoding c-Abl and a nucleic acid encoding p300 to said tumor, wherein said nucleic acid is operably linked to a promoter active in eukaryotic cells in an amount effective to increase p53-mediated apoptosis in cells thereof.
23. The method of claim 20, wherein the activity level is increased by providing an agent to said tumor that increases the expression or stability of at least one of c-Abl and p300 in an amount effective to increase p53-mediated apoptosis in cells thereof.
24. The method of claim 21, wherein said polypeptide is provided via intratumoral injection
25. The method of claim 22, wherein said nucleic acid is provided via intratumoral injection.
26. The method of claim 23, wherein said agent is provided via intratumoral injection.
27 The method of claim 20, wherein said tumor comprises cells which lack p53 activity, and said method further comprises providing to said tumor cell a nucleic acid encoding a wild-type p53 operably linked to a promoter active in eukaryotic cells
28 The method of claim 20, further comprising contacting said cell with ionizing radiation
29 The method of claim 20, further comprising contacting said cell with a chemotherapeutic agent
30 A method of screening a candidate substance for p53 -stimulatory activity comprising the steps of
(i) providing a eukaryotic cell expressing a functional p300 polypeptide, (ii) contacting said cell with said candidate substance; and
(iii) determining the effect of said candidate substance on the p300 level of said cell,
wherein an increase in the p300 level in said cell, as compared to an untreated cell, indicates that said candidate substance increases p53 activity.
31 The method of claim 30, wherein said p300 level is measured by Western blot or ELISA.
32. The method of claim 30, wherein said candidate substance is a nucleic acid encoding a polypeptide operably linked to a promoter active in eukaryotic cells and said contacting comprises transferring said nucleic acid into said cell
33. The method of claim 32, wherein said transferring is achieved by transfection, lipofection, protoplast fusion, bombardment, electroporation or viral infection.
34 A method of screening a candidate substance for p53-stimulatory activity comprising the steps of
(i) providing a eukaryotic cell expressing a functional p300 polypeptide, (ii) contacting said cell with said candidate substance, and
(iii) determining the effect of said candidate substance on the p300 level of said cell,
wherein an increase in the p300 level in said cell, as compared to an untreated cell, indicates that said candidate substance increases p53 activity
35 The method of claim 34, wherein said c-Abl level is measured by Western blot or ELISA
36 The method of claim 34, wherein said candidate substance is a nucleic acid encoding a polypeptide operably linked to a promoter active in eukaryotic cells and said contacting comprises transferring said nucleic acid into said cell
37 The method of claim 36, wherein said transferring is achieved by transfection, lipofection, protoplast fusion, bombardment, electroporation or viral infection
38 Use of at least one of a p300 and a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase p53-mediated apoptosis in a cell
39 Use of at least one of a nucleic acid encoding a p300 polypeptide and a nucleic acid encoding a c-Abl polypeptide for the preparation of a pharmaceutical composition effective to increase apoptosis in a cell
40 Use of a p300 polypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer
41. Use of a p300 pojypeptide or gene coding therefor for the preparation of a pharmaceutical composition for the treatment of cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37313/97A AU3731397A (en) | 1996-07-18 | 1997-07-18 | Methods and compositions for modulation of growth response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2212496P | 1996-07-18 | 1996-07-18 | |
US60/022,124 | 1996-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998003195A1 WO1998003195A1 (en) | 1998-01-29 |
WO1998003195A9 true WO1998003195A9 (en) | 1998-06-04 |
Family
ID=21807939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012498 WO1998003195A1 (en) | 1996-07-18 | 1997-07-18 | Methods and compositions for modulation of growth response |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3731397A (en) |
WO (1) | WO1998003195A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927612B2 (en) | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
AU2002303390A1 (en) | 2001-04-18 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Induction of apoptosis by cellular stress |
CN101138634A (en) | 2006-09-07 | 2008-03-12 | 于保法 | Composition for treating tumour |
CN107106531A (en) | 2014-11-26 | 2017-08-29 | 于保法 | The enhanced chemoimmunotherapy of chemical induction immunotherapy method haptens in minimally invasive accurate individuation knubble |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747469A (en) * | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US5658784A (en) * | 1994-04-14 | 1997-08-19 | Dana-Farber Cancer Institute, Inc. | Nucleic acid encoding transcription factor p300 and uses of p300 |
-
1997
- 1997-07-18 AU AU37313/97A patent/AU3731397A/en not_active Abandoned
- 1997-07-18 WO PCT/US1997/012498 patent/WO1998003195A1/en active Application Filing
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5958892A (en) | 2-methoxyestradiol-induced apoptosis in cancer cells | |
Correia et al. | Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment | |
Zhang et al. | TRAF6 restricts p53 mitochondrial translocation, apoptosis, and tumor suppression | |
Altomare et al. | Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth | |
Degenhardt et al. | BAX and BAK mediate p53-independent suppression of tumorigenesis | |
AU724212B2 (en) | Down-regulation of DNA repair to enhance sensitivity to P53-mediated suppression | |
Nanos-Webb et al. | Targeting low molecular weight cyclin E (LMW-E) in breast cancer | |
WO2009102986A1 (en) | Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox1 inhibitor | |
Delia et al. | Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations | |
Zhao et al. | An oncogenic tyrosine kinase inhibits DNA repair and DNA-damage-induced Bcl-xL deamidation in T cell transformation | |
Hall et al. | A brief staurosporine treatment of mitotic cells triggers premature exit from mitosis and polyploid cell formation | |
Truong et al. | Direct transcriptional regulation of MDM2 by Fli-1 | |
Wen et al. | Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models | |
Sionov et al. | Apoptosis by p53: mechanisms, regulation, and clinical implications | |
WO1998003195A9 (en) | Methods and compositions for modulation of growth response | |
WO1998003195A1 (en) | Methods and compositions for modulation of growth response | |
WO1997008184A1 (en) | Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators | |
Kudoh et al. | Protein expression of cell cycle regulator, p27Kip1, correlates with histopathological grade of non‐Hodgkin's lymphoma | |
CA2471967A1 (en) | Wt1 antisense oligos for the inhibition of breast cancer | |
Ling | Role of 14-3-3τ in autophagy and role of EDD in p53 regulation | |
Lukošiūtė-Urbonienė | EFFECTS OF EPIGENETIC ALTERATIONS ON THE APOPTOSIS REGULATING PROTEINS IN PANCREATIC CANCER | |
Ramesh et al. | Retroviral Transfer of the Herpes Simplex Virus-Thymidine Kinase (HSV-tK) Gene for the Treatment of Cancer | |
Fan et al. | Item Type Article | |
Flatt | Analysis of p53 signaling pathways after cell stress: A role for p53 in G2 cell cycle checkpoint response | |
Mihich et al. | Eleventh Annual Pezcoller Symposium: Molecular Horizons in Cancer Therapeutics |